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Summary
Malaria remains a global health problem causing more than 200 million clin-
ical cases and 400 000 deaths each year. Athough most malaria infections
remain uncomplicated, various complications, including cerebral malaria, se-
vere malarial anemia, placental malaria and malaria-associated acute respira-
tory syndrome (MA-ARDS) cause the majority of deaths. MA-ARDS occurs
mainly in adults and constitutes an important but insufficiently studied com-
plication of malaria. MA-ARDS is characterised by lung edema, severe lung
inflammation and impaired gas exchange. Currently, adequate treatment for
this syndrome is not available. Therefore, our group developed an in vivo
model of MA-ARDS with C57BL/6 mice infected with Plasmodium berghei
NK65 (PbNK65). In this model, extremely high doses of glucocorticoids (GCs)
blocked development of MA-ARDS, but the highest doses acceptable in the
clinic did not prevent the pathology. Furthermore, GCs failed to inhibit the ex-
pression of pro-inflammatory cytokines and chemokines in the lungs of infected
mice. This suggests that malaria decreases GC sensitivity, but the mechanisms
underlying GC resistance in malaria remain unclear.
This thesis aimed to identify molecular mechanisms of GC resistance in
MA-ARDS. We established an in vitro model of GC resistance in malaria with
lung endothelial cells. We investigated GC sensitivity of mouse microvascu-
lar lung endothelial cells stimulated with interferon-γ (IFN-γ) and PbNK65.
Upon challenge with IFN-γ alone, dexamethasone inhibited the expression of
CCL5 (RANTES), CCL2 (MCP-1) and CXCL10 (IP-10). Accordingly, whole
transcriptome analysis revealed that dexamethasone differentially affected sev-
eral gene clusters and in particular inhibited a large cluster of IFN-γ-induced
genes, including chemokines. This indicates that lung endothelial cells stimu-
lated with IFN-γ remain GC sensitive. In contrast, combined stimulation with
IFN-γ and PbNK65 extract impaired inhibitory actions of GCs on chemokine
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release reflecting GC resistance. However, the resistance did not affect the
capacity of the GC receptor to accumulate in the nucleus. Subsequently, we
studied the effects of GCs on STAT1 and MAPK pathways. Dexamethasone
did not decrease phosphorylation and protein levels of STAT1. In contrast,
dexamethasone inhibited the IFN-γ-induced activation of two MAPKs, JNK
and p38. However, PbNK65 extract abolished the inhibitory effects of GCs
on MAPK signaling, inducing GC resistance. Overall, in this thesis we de-
scribe molecular mechanisms of regulation of IFN-γ-induced inflammation by
GCs. We also identify PbNK65 as a novel inducer of GC resistance in lung en-
dothelial cells due to sustained MAPK activity. This work therefore provides
novel insights and leads to the development of therapeutic strategies against
MA-ARDS.
viii
1 Introduction
1.1 Malaria remains a global health challenge
Malaria remains a life-threatening disease with negative impact on social and
political stability. In 2015, 212 million clinical cases of malaria and approxi-
mately 429 000 deaths were reported (WHO website1). Malaria is caused by
Plasmodium parasites, which belong to the Apicomplexa Phylum. Five species
of Plasmodium can infect humans: P. falciparum, P. vivax, P. knowlesi, P.
malariae and P. ovale. However, P. falciparum is responsible for the majority
of deaths and infections. The Plasmodium parasite has a complicated life cy-
cle. A female Anopheles mosquito injects sporozoites into the skin, which enter
the blood stream and migrate into the liver. There, the parasites mature and
undergo asexual replication. New merozoites released from hepatocytes enter
the blood stream and infect red blood cells (RBCs). The parasite population
grows exponentially in RBCs due to repeated cycles of invasion, replication and
release. Some parasites differentiate into gametocytes within RBCs. These ga-
metocytes can be taken up by a mosquito, in which sexual replication takes
place resulting in a new infective mosquito. The first symptoms of malaria ap-
pear 7-15 days post infection during the erythrocytic stage and include fever,
headache, muscle pain, chills and vomiting [1].
Most malaria infections remain uncomplicated. However, various complica-
tions including cerebral malaria, severe malarial anemia, placental malaria and
malaria-associated acute respiratory distress syndrome (MA-ARDS) cause the
majority of deaths [1, 2]. For example, cerebral malaria is a complication of
P. falciparum infections that causes high mortality and post-recovery neuro-
cognitive disorders. This complication is most common in sub-Saharan Africa.
There, cerebral malaria is rare in adults and occurs mainly in children under
1http://www.who.int/malaria/en/
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five years (WHO website1). Cerebral malaria also occurs in South East Asia,
where malaria transmission is not intense enough to result in semi-immunity.
In South East Asia, cerebral malaria mainly occurs in adults and older children
[3]. Binding of infected RBCs (parasite sequestration) to the brain microvas-
culature plays a key role in the development of cerebral malaria [4]. In adults,
cerebral malaria often occurs together with renal and respiratory failure. How-
ever, children suffer mainly from rapid onset of coma, anemia and seizures
[5, 3].
1.2 MA-ARDS is a lethal and incompletely understood
complication of malaria
MA-ARDS, occurs mainly in adults and constitutes an important but insuffi-
ciently studied complication of malaria [6, 7]. Patients with severe falciparum,
vivax, and knowlesi malaria may suffer from MA-ARDS and this syndrome
may even occur several days after anti-malarial treatment [7]. Most reported
MA-ARDS cases arise in low-transmission areas or in non-immune travellers.
Moreover, pregnant women with placental malaria may develop MA-ARDS.
Currently, adequate treatment for MA-ARDS is not available [2, 8].
MA-ARDS is characterized by lung edema and impaired gas exchange [2].
Parasite-infected erythrocytes adhere to the endothelium in the lungs and this
triggers leukocyte infiltration and pro-inflammatory cytokine production [2, 6].
Endothelial cells are activated by these cytokines and are likely the first cells
altered in the lungs during acute respiratory distress syndrome (ARDS) [9].
Also, parasite products such as haemozoin and histidine-rich protein II have
been shown to activate endothelium and increase endothelial barrier permeabil-
ity [10, 11, 12]. Increased permeability of the microvascular barrier is typical
in acute inflammation and plays a central role in the pathogenesis of ARDS
1http://www.who.int/malaria/en/
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[9, 13, 8]. Moreover, it results in interstitial edema and facilitates leukocyte
infiltration. Immune cells play a crucial role in the development of MA-ARDS.
Abundant monocyte and macrophage infiltrates are found both inside the blood
capillaries and in the interstitium in postmortem histological sections of pa-
tients with MA-ARDS [14]. Furthermore, lymphocytes and a small number of
neutrophils are present [15]. In murine MA-ARDS, especially CD8+ T cells are
pathogenic [8]. Recent studies also suggested neutrophils to play a detrimental
role, whereas monocytes appeared rather protective by phagocytosing infected
erythrocytes [16, 17].
1.3 Sequestration and endothelial activation in malaria
Sequestration of infected RBCs in the microvessels allows the parasite to avoid
clearance in the spleen. In mouse models of cerebral malaria, P. berghei ANKA-
infected RBCs bind to murine brain and lung endothelial cells [18]. In humans,
sequestration of P. falciparum-infected RBCs is mediated by interactions be-
tween members of P. falciparum erythrocyte membrane protein 1 (PfEMP1)
family, encoded by var genes, and specific receptors on the endothelial cells.
Switching between var genes enables immune evasion and affects the binding
specificity of infected RBCs. Infected RBCs also form clusters with non-infected
erythrocytes and this process is called rosetting [19].
Various receptors on the endothelial surface have been implicated in seques-
tration. Many parasite isolates bind to CD36, which plays an important role
in innate immunity and phagocytosis of parasites during malaria. This has
been associated with mild malaria [20, 21]. In human dermal endothelial cells,
cytoadherence of infected RBCs to CD36 depends on Src family kinase activity.
Treatment of human dermal endothelial cells with Src family kinase inhibitor
significantly reduced adhesion of infected RBCs [22]. CD36 also mediates se-
questration in adipose tissue and lungs in mouse models with P. berghei [23].
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Two specific PfEMP1 subtypes containing domain cassettes (DCs) 8 and 13
are associated with severe childhood malaria. The interaction between DC8
or DC13 PfEMP1 and endothelial lining is mediated by endothelial protein C
receptor (EPCR). EPCR is mainly involved in anti-inflammatory and cytopro-
tective effects of activated protein C [4].
Intercellular adhesion molecule 1 (ICAM-1) is another endothelial receptor
that mediates sequestration in malaria. P. falciparum and P. vivax have been
shown to bind to ICAM-1 [24, 25]. ICAM-1 also mediates sequestration in the
P. chabaudi model [26]. Various cytokines enhance the expression of ICAM-1.
In subcutaneous endothelial cells from patients with complicated malaria, tu-
mor necrosis factor (TNF) induced higher expression of ICAM-1 compared to
uncomplicated controls [27]. TNF also synergizes with interferon-γ (IFN-γ) to
enhance ICAM-1 expression in mouse brain endothelial cells [28]. Other adhe-
sion receptors such as platelet endothelial cell adhesion molecule 1 (PECAM-1)
and vascular cell adhesion molecule 1 (VCAM-1) are also involved in seques-
tration in malaria [29, 30].
Sequestration of infected RBCs disrupts blood flow, decreases endothelial
barrier integrity and activates pro-inflammatory and coagulation pathways [31].
Ruptured P. falciparum-infected RBCs activate β-catenin and disrupt inter-
endothelial junctions in human brain endothelial cells. Blockade of the an-
giotensin II type 1 receptor (AT1) or activation of the angiotensin II type
2 receptor (AT2) inhibited infected RBCs-induced activation of β-catenin and
preserved endothelial barrier integrity [32]. P. falciparum-derived histones have
also been shown to damage endothelial barrier [33]. The underlying mechanism
involves impaired expression of junctional proteins and cell death. Stimulation
of endothelial cells with P. falciparum histones also induces production of var-
ious pro-inflammatory mediators including interleukin (IL)-8, CC chemokine
ligand (CCL)2, also known as monocyte chemoattractant protein 1 (MCP-1)
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and cyclooxygenase 2 (COX2) via Src and p38 mitogen-activated protein ki-
nase (MAPK) signaling pathways. Brain endothelial cells internalize and cross-
present P. berghei ANKA antigens in the presence of IFN-γ and this confers
susceptibility to killing by CD8+ T cells leading to further disruption of the
endothelial barrier [34].
The Tie receptors (Tie1 and Tie2) and their angiopoietin ligands (ANG1-
ANG4) constitute a receptor Tyr kinase system in the vasculature. ANG-Tie
controls vessel quiescence and regulates late stages of angiogenesis [35]. ANG1
exerts its anti-inflammatory effects through inhibition of vascular endothelial
growth factor (VEGF)-induced expression of ICAM-1, VCAM-1 and E-selectin
[36]. Moreover, ANG1 prevents VEGF and TNF-induced expression of the pro-
coagulatory molecule tissue factor (TF) [37]. ANG2 was described as a ligand
that antagonizes ANG1 activity on Tie2 and acts as a switch between the
quiescent and inflamed state of endothelium [38, 39]. ANG2 also controls late
steps of leukocyte adhesion. Furthermore, ANG2 sensitizes endothelial cells
towards TNF and modulates TNF-induced expression of adhesion molecules
[39]. Decreased ANG1 expression and soluble Tie-2 expression is associated
with disease severity in patients with severe malaria. ANG1 also preserves
endothelial barrier integrity in a mouse model of cerebral malaria [40]. Another
study showed that in patients with malaria platelets release ANG1, possibly to
mitigate harmful effects of ANG2 on endothelium [41].
1.4 Endothelial activation during inflammation
At rest endothelial cells present a nonreactive surface at the interface between
blood and tissue. Upon activation the endothelium becomes a major player in
the generation of the inflammatory response [42]. Pro-inflammatory cytokines
produced by immune cells activate the endothelium and mediate leukocyte re-
cruitment. Endothelial selectins such as E- and P-selectin capture leukocytes
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from the blood flow and mediate rolling [43]. This slows down the circulat-
ing leukocytes and enables chemokines, localized on the endothelial surface, to
interact with their receptors on leukocytes leading to integrin activation [44].
Pro-inflammatory mediators such as TNF, IL -1, -17A, -18, -33, -36γ and inter-
feron (IFN) -α, -β, -γ stimulate the endothelium to produce various chemokines
CCL2 (MCP-1), CCL20 (also known as macrophage inflammatory protein-3α
(MIP-3α)), CXC chemokine ligand (CXCL)1 (also known as growth related
oncogene-α (GRO-α)), CXCL8 (also known as IL-8), CXCL9 (also known as
monokine induced by IFN-γ (MIG)), CXCL10 (also known as interferon-γ-
induced protein 10 (IP-10)), CXCL11 (also known as interferon-inducible T
cell α chemoattractant (I-TAC)) and also integrin ligands such as ICAM-1 and
VCAM-1 [42, 45, 46, 47, 48, 49, 50, 51]. In contrast, IL-10 and IL-37 decrease
CXCL8 (IL-8) and ICAM-1 expression in endothelial cells [52, 53]. ICAM-1
and VCAM-1 control firm adhesion and leukocyte crawling on the endothelial
surface until they transmigrate through the endothelial barrier [54]. PECAM-1
controls localization of junctional proteins such as VE-cadherin and β-catenin
and mediates leukocyte extravasation to the sites of inflammation [55].
1.5 Glucocorticoids are efficient anti-inflammatory
molecules
1.5.1 Endogenous glucocorticoid synthesis and glucocorticoid re-
ceptor
Endogenous glucocorticoids (GCs) (cortisol in humans and corticosterone in
rodents) are steroidal hormones synthesized from cholesterol in the adrenal
cortex. Activation of hypothalamic-pituitary-adrenal (HPA) axis by stress,
physical activity and trauma results in GCs production and release. The HPA
axis is also activated by pro-inflammatory cytokines such as TNF. This re-
sults in GC secretion and inhibition of inflammation. GC activity is locally
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regulated by extracellular binding proteins and intracellular enzymes. Only
approximately 5% of circulating cortisol remains free and active. The rest
binds to corticosteroid-binding globulin (CBG) [56].
Two distinct enzymes that regulate tissue specific metabolism of GCs exist.
11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) converts inactive cortisone
into cortisol. This isoform is expressed in liver, adipose tissue, brain, lungs,
inflammatory cells, and gonads. In contrast, 11β-hydroxysteroid dehydroge-
nase 2 (11β-HSD2) inactivates GCs and allows aldosterone access to miner-
alocorticoids receptors in the classic aldosterone target tissues including distal
nephrons, colonic epithelium and sweat and salivary glands [57, 58]. Moreover,
two different receptors fine tune GC signaling: mineralocorticoid receptor (MR)
and glucocorticoid receptor (GR). High expression of MR has been reported
in aldosterone target tissues such as kidney, colon, salivary glands, and spe-
cific brain regions. In contrast, GR is ubiquitously expressed [58]. MR binds
with high-affinity both mineralocorticoids and GCs whereas GR is selective for
GCs [59, 60]. Therefore, the occupancy of GR by GCs increases during stress
and pharmacotherapy [58].
1.5.2 GR structure and isoforms
GR (NR3C1) mediates physiological and pharmacological effects of GCs. GR
belongs to the nuclear receptor family of ligand-activated transcription fac-
tors. GR has a modular structure and is comprised of 3 domains (Figure 1):
an N-terminal transactivation domain (NTD), a central DNA binding domain
(DBD), and a C-terminal ligand-binding domain (LBD) [61]. The NTD do-
main is a primary target for posttranslational modifications. Moreover, NTD
contains activation function (AF)-1 which interacts with coregulators and the
basal transcription machinery [62]. The DBD contains 2 zinc finger motifs
that bind target DNA sequences – glucocorticoid response elements (GREs)
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[61]. DBD and LBD are separated by a flexible region called hinge region
(Figure 1). The LBD, which forms a hydrophobic pocket for binding GCs,
also contains a second AF-2 domain. LBD and the DBD-hinge region contains
nuclear localization signal (NLS)1 and NLS2 [62].
The human GR gene contains 9 exons. Alternative splicing in exon 9 gen-
erates two GR isoforms: GRα and GRβ (Figure 1). GRα is the classic GR
protein that mediates GC actions. GRβ resides constitutively in the nucleus
and does not bind ligands. GRβ is expressed in many tissues and cell types
but generally at lower levels than GRα and has been shown to inhibit GRα.
GRβ competes with GRα for GRE binding and transcriptional coregulators.
Furthermore, GRβ forms inactive dimers with GRα [62]. GRγ, GR-A, and
GR-P are additional GR splice isoforms [61]. The expression of GRγ correlates
with GC resistance in childhood acute lymphoblastic leukemia [63]. GR-A is
not well studied whereas GR-P is expressed in GC-resistant cancer cells [62].
Alternative translation initiation generates eight GRα isoforms with pro-
gressively shorter N-terminus: GRα-A, -B, -C1, -C2, -C3, -D1, -D2, and -D3,
adding another level of complexity to the GR biology. Other GR splice vari-
ants would also generate various translational isoforms. GRα isoforms exhibit
a similar ligand binding affinity and similar GRE binding capacity. However,
their cellular localization differs [61]. Human GRα-D (hGRα-D) constitutively
resides in the nucleus. In contrast, hGRα-A, -B and C localize in the cyto-
plasm and translocate to the nucleus upon ligand binding. Furthermore, each
GRα isoform regulates a unique and common set of genes [64]. All isoforms
GR are also subject to a variety of posttranslational modifications including
phosphorylation, ubiquitination and SUMOylation (Figure 1) [62].
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Figure 1: Domain structure of the human GR (A) with its target residues for
posttranslational modifications (B). AF – activation function, DBD – DNA-
binding domain, HR – hinge region, LBD – ligand binding domain, NLS –
nuclear localization signal, NTD – N-terminal domain, P – phosphorylation, S
– sumoylation, U – ubiquitination.
1.5.3 Molecular mechanism of GC action
In the absence of ligand GR resides mainly in the cytoplasm in complex with
several proteins: Hsp90, Hsp70, p23, FKBP51 and FKBP52 [65]. Upon ligand
binding GR dissociates from the multiprotein complex and translocates into
the nucleus. Inside the nucleus GR (as a homodimer) binds to the consensus
GRE sequence GGAACAnnnTGTTCT, which is an imperfect palindrome [62].
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Upon GRE binding GR undergoes conformational changes leading to coregula-
tor and chromatin-remodeling complexes recruitment. This process influences
the activity of RNA polymerase II [61]. The consensus GRE sequence, often re-
ferred to as positive GRE, has been shown to mediate induction of various GR-
dependent genes including sphingosine kinase 1 (SphK1) and TGF-stimulated
clone 22 domain protein-3 (Tsc22d3), also known as glucocorticoid-induced
leucine zipper (GILZ) [66, 67]. However, only a small subset of GREs are occu-
pied by GR. The specific sites where GR binds vary among tissues and depend
on chromatin accessibility [68]. Activator protein 1 (AP-1) plays an important
role in the maintenance of baseline chromatin accessibility and facilitates GR
recruitment [69].
Negative GREs (nGREs), which mediate GR-dependent transcriptional in-
hibition, have been also identified in the genome [70]. In contrast to the posi-
tive GRE sequence, the consensus nGRE sequence CTCC(n)0-2GGAGA, which
contains a variable spacer that ranges from 0 to 2 nucleotides, can be occupied
by 2 GR monomers that do not dimerize [62]. Hudson and colleagues showed
that in the nGREs, each GR monomer is oriented away from the second one pre-
venting interaction between dimerization loops [71]. Ligand bound GR might
also influence gene expression via protein-protein interactions with other tran-
scription factors (TFs) bound to DNA. For example, the GR signal transducer
and activator of transcription (STAT)5 complex activates gene transcription
[72, 73]. In contrast, GR recruitment to DNA bound transcription factors such
as AP-1 and nuclear factor κB (NF-κB) inhibits their activity. This is a primary
mechanism by which GCs inhibit inflammation. GR interferes with the trans-
activating capacity of p65 and c-Jun [62]. Several nonexclusive mechanisms of
NF-κB inhibition by GR have been reported including GR-mediated tethering
of the NF-κB p65 subunit, histone deacetylase 2 (HDAC2) recruitment by GR
to the NF-κB-dependent promoters, and blockade of transcriptional elongation
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[74]. Moreover, GR activation blocks NF-κB interaction with chromatin [75].
AP-1, which can be tethered by GR, also regulates GR binding to DNA and
facilitates productive GR-chromatin interactions [69]. Furthermore, GR can
also inhibit gene transcription in a composite manner via binding to GRE and
physical association with AP-1 bound to DNA [76].
1.5.4 Non-genomic actions of GR
GR can also exert some of its actions via non genomic mechanisms that do not
require protein synthesis and occur within a few seconds to minutes [62]. Nonge-
nomic effects of GCs are mediated through cytosolic and membrane bound GR
[61]. Dexamethasone blocks arachidonic acid release in A549 cells via inhibi-
tion of recruitment of signaling factors to the epidermal growth factor receptor.
This inhibition is GR-dependent but transcription-independent [77]. GCs in-
duce rapid serine phosphorylation and membrane translocation of ANXA1 via
nongenomic pathways in a human folliculostellate cell line resulting in inhi-
bition of adrenocorticotropic hormone (ACTH) secretion [78]. In thymocytes,
GR translocates to mitochondria and induces apoptosis or affects mitochondrial
gene expression [79].
1.5.5 Effects of GCs on immune cells
The effects of GCs on immune cells have extensively been studied. For a com-
plete overview of the literature on this subject the reader is referred to ex-
tensive reviews [56, 80]. Here, several examples of interesting effects of GCs
on specific leukocytes populations are described. In B cells, GCs induce cy-
totoxic and growth-suppressive effects via induction of GILZ. GILZ KO mice
develop B lymphocytosis due to increased B cell survival. Moreover, impaired
B cells apoptosis in those mice correlates with enhanced NF-κB activity and
Bcl-2 expression [81]. In contrast, GCs have been shown to inhibit apoptosis
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in neutrophils [82]. Dexamethasone induces dichotomic effects, dependent on
the cytokine milieu, in NK cells. It initially suppresses IFN-γ production but
enhances proliferation and survival in NK cells challenged with IL-2 and IL-
12. Furthermore, NK cells restimulated with IL-2, IL-12 and dexamethasone
showed enhanced IFN-γ production [83].
GCs regulate multiple aspects of T cell physiology. For example, in patients
with multiple sclerosis (MS), high-dose GCs induce apoptosis in CD4+T cells
[84]. Moreover, GCs inhibit IL-2 release and T cell receptor (TCR) signaling
as well as phosphorylation of several molecules down-stream of TCR including
p38 mitogen-activated protein kinase (p38 MAPK), c-Jun N-terminal kinase
(JNK), protein kinase (PK)B and PKC [85, 86]. GCs have also been shown
to induce regulatory T cells that express the transcription factor forkhead box
P3 (FoxP3). The underlying mechanism is induction of GILZ by GCs. GILZ
enhances transforming growth factor β (TGF-β) signaling and activates FoxP3
expression. In vivo, GILZ overexpression increases T reg cell number, whereas
GILZ KO impairs generation of peripheral regulatory T cells [87]. Interestingly,
Th2 cells produce a steroid pregnenolone that inhibits Th cell proliferation and
B cell class switching. This de novo pregnenolone synthesis might represent
a unique way of Th2 responses to restore immune homeostasis [88].
GCs impair dendritic cells (DCs) differentiation and induce a population
of DCs incapable of inducing effective immune response. These DCs fail to
prime Th1 cells [89]. GC administration during DC maturation reduces IL-
12 p70, TNF production and T cell stimulatory function. In patients with
systemic autoimmunity, GCs decrease the number of myeloid DCs and abro-
gated plasmacytoid DCs. Although GCs enhanced toll-like receptor (TLR)2,
3, and 4 expression on DCs, challenge with TLR ligands failed to induce mat-
uration [90]. However, the effects of GCs on DCs depend on the maturation
state since the inhibitory effect of GCs on DCs was absent upon challenge with
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lipopolysaccharide (LPS) [89]. GCs have also been shown to induce apoptosis
in human plasmacytoid pre-dendritic cells [91].
The effects of GCs on macrophages are concentration-dependent. Low con-
centrations of GCs enhance pro-inflammatory cytokine and nitric oxide (NO)
expression. In contrast, high doses of GCs suppress macrophage function [92].
These data are in contrast with another study from Van de Garde and col-
leagues who compared the transcriptome of human macrophages matured in
the presence or absence of high-dose GCs and the ability to initiate or main-
tain classic activation [93]. Macrophages were challenged with acute LPS and
chronic IFN-γ stimulation. Long-term stimulation with GCs weakens adap-
tive immune signature components of IFN-γ and LPS gene profile via down-
regulation of major histocompatibility complex (MHC) class II, but strength-
ens innate signature components through induction of chemokines that attract
leukocytes. In general, high doses GCs do not suppress macrophage function,
but shift the balance between innate and adaptive immunity. GCs have also
been shown to inhibit p38 pathways in macrophages challenged with LPS [94].
In monocytes, GCs induce anti-inflammatory genes such as GILZ and IL-10
leading to M2 polarity [95].
1.5.6 Effects of GCs on endothelial cells
It becomes more and more clear that GCs also regulate multiple aspects of en-
dothelial physiology (Figure 2). GCs inhibit pro-inflammatory signaling path-
ways in endothelium and induce protective molecules that maintain endothe-
lial function, in particular upon inflammation. For instance, dexamethasone
blocks nuclear translocation of NF-κB and reduces the binding of AP-1 and
GATA to DNA in endothelial cells [96]. GCs induce map kinase phosphatase-1
(MKP-1), also known as dual-specificity phosphatase-1 (DUSP1), which in-
hibits MAPK signaling pathways, and tristetraprolin (TTP), also known as
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(ZFP36), which destabilizes mRNAs of pro-inflammatory cytokines [97, 98].
Annexin A1 (AnxA1), induced by GCs in endothelium, causes leukocyte de-
tachment and regulates BBB integrity [99, 100, 101]. Moreover, AnxA1 inhibits
phospholipase A2, an enzyme that releases arachidonic acid from phospholipids
to produce pro-inflammatory mediators such as prostaglandins and leukotrienes
via cyclooxygenase [102].
GCs inhibit the endothelial production of several pro-inflammatory cy-
tokines and chemokines such as IL-6, IL-17F, CXCL8 (IL-8) and CCL2 (MCP-
1) [98, 97, 103]. GCs also down-regulate ICAM-1, VCAM-1 and E-selectin
[104, 105, 106]. Moreover, GCs reduce the levels of soluble forms of ICAM-1,
VCAM-1 and E-selectin (sICAM-1, sVCAM-1, sE-selectin) [107]. Interestingly,
GCs may also down-regulate HLA-DR in IFN-γ-stimulated endothelial cells
[104]. Overall, GCs decrease leukocyte transmigration across the endothelium,
thus limiting inflammation [108].
GCs also increase the activity of eNOS – a critical mediator of vascular
integrity [109]. Release of NO in the lumen inhibits platelet aggregation and
leukocyte adhesion [110]. Conversely, Iuchi et al. showed that GC excess in-
duces reactive oxygen species and peroxynitrite formation, with possible detri-
mental effects on the vasculature [111].
Disruption of the endothelial barrier integrity is a common feature of vari-
ous diseases including MS and stroke and leads to edema [112]. GCs preserve
endothelial barrier integrity through up-regulation of junctional proteins such
as occludin, claudin-5 and VE-cadherin [113, 114, 115] and down-regulation of
matrix metallopeptidase 9 (MMP-9) – an enzyme involved in junctional pro-
tein cleavage [116, 117, 118]. GCs also inhibit MMP-9 via induction of tissue
inhibitor of metalloproteinases (TIMP) – TIMP-3 and TIMP-1 [119, 117]. How-
ever, the induction of TIMP-1 seems controversial, since contradictory results
exist [119]. Since MMP-9 is able to cleave CXCL8 (IL-8) and drastically po-
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tentiates its activities [120], it is tempting to speculate that down-regulation of
MMP-9 by GCs further affects neutrophil chemoattraction at the endothelial
surface.
In summary, GCs influence endothelial barrier integrity, inhibit various pro-
inflammatory transcription factors, and induce protective molecules in endothe-
lium (Figure 2). Investigation of molecular mechanisms of GC action in en-
dothelium will enable comparison of these to the extensive data on regulation
of inflammation by GC in other cell types.
1.5.7 GCs in the clinic
GCs have been prescribed as therapy for various inflammatory diseases includ-
ing rheumatoid arthritis, asthma and multiple sclerosis since the 1950s [56, 121].
Synthetic GCs are more potent immunoregulators than endogenous ones be-
cause they are not targets of endogenous inhibitors such as 11β-HSD and CBG.
Furthermore, synthetic GCs bind the GR with higher affinity and the MR with
lower affinity than endogenous hormones [56]. However, GC therapy has two
major drawbacks: side-effects and GCs resistance.
Although GCs have been an effective therapy in chronic inflammatory dis-
eases, the long term therapy with GCs results in severe side-effects including
diabetes, bone frailty, muscle wasting, fat depot changes, hypertension, sus-
ceptibility to infections, and mood disorders [122]. Different GR conforma-
tions reflect the complex nature of GR and exert diverse anti-inflammatory
profiles. GR agonists currently used in the clinic might activate multiple anti-
inflammatory actions of GR. Such an excessive non-specific anti-inflammatory
response results in side-effects and limits the beneficial effects of the therapy.
Since the biology of the GR is complex, selective GR-mediated activation of
anti-inflammatory profiles provides a means to develop disease-tailored thera-
pies. For example, treatment that induces formation of GR monomers might
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GRGCOccludin ↑
Claudin-5 ↑
VE-cadherin ↑
ICAM-1 ↓ VCAM-1 ↓ E-selectin ↓
GATA and AP-1 DNA binding ↓
Blood vessel lumen
Endothelium
NF-κB translocation ↓
p50p65
eNOS activity ↑
MKP-1 ↑
IL-6 ↓
IL-17F ↓
AnxA1 ↑
MMP-9 ↓
ROS ↑
CCL2 (MCP-1) ↓
TTP ↑
TIMPs ↑ sICAM-1 ↓
sVCAM-1 ↓
sE-selectin ↓
CXCL8 (IL-8) ↓
Figure 2: GCs exert specific actions in endothelial cells. In general, GCs
have a variety of cell-type specific effects. This figure depicts GC actions that
have been described in endothelium. After entering an endothelial cell, GCs
bind to GR and translocate to the nucleus. GR bound to GCs inhibits pro-
inflammatory pathways by limiting GATA and AP-1 DNA binding and NF-κB
translocation. GCs decrease levels of adhesion molecules (VCAM-1, ICAM-1
and E-selectin) and also their soluble forms and MMP-9 while increasing lev-
els of junctional proteins – occludin, claudin-5 and VE-cadherin. GCs induce
protective molecules such as AnxA1, TTP, MKP-1 and TIMPs. Furthermore,
GCs reduce levels of IL-6, IL-17F, CXCL8 (IL-8) and CCL2 (MCP-1). Stimu-
lation with GCs increases the activity of eNOS – a critical mediator of vascular
integrity. Induction of ROS represents detrimental effects of GC excess on the
vasculature.
help to reduce the number of side effects during GC therapy in chronic inflam-
matory diseases. In contrast, patients with acute inflammation would benefit
from skewing the GR phenotype towards dimers [121]. Animal models suggest
that GR-induced anti-inflammatory genes such as SphK1 confer protection
against acute inflammation [67].
GC resistance has been reported in various diseases such as asthma and
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chronic obstructive pulmonary disease (COPD) [123] and in different cells types
including peripheral blood mononuclear cells (PBMCs), B cells and alveolar
macrophages. A wide range of mechanisms causing GC resistance in these
cell types have been described, including increased GRβ expression, post-
translational GR modification, impaired nuclear translocation of GR, reduced
MKP-1 (DUSP1) expression and decreased activity of HDAC2 [124, 125, 126,
127, 128]. Furthermore, deregulated microRNA expression might contribute
to GC resistance. For example, microRNA-124 has been shown to target GR
and reduce its levels in acute lymphoblastic leukemia (ALL) [129]. Also in
ALL, NLRP3-CASP1 inflammasome might cleave GR leading to reduced GR-
mediated transcriptional response and GC resistance [130].
1.6 Regulation of endothelial GC sensitivity
A limited number of studies addressed GC sensitivity of endothelium and un-
covered several mechanisms that regulate the response of endothelium to GCs
(Figure 3). In dexamethasone-resistant human umbilical vein endothelial cells
(HUVECs), GR interacted more strongly with BCL2-associated athanogene 1
(BAG1) protein than in dexamethasone-sensitive HUVECs [131]. In general,
BAG1 is a cytoplasmic protein, which can translocate to the nucleus and bind
to DNA, decreasing GR transactivation [132]. BAG1 also interferes with GR
folding through interaction with Hsp70 [133]. Moreover, BAG1 may target in-
teracting proteins for proteasomal degradation [134]. In HUVECs, proteasome
inhibition increased GR protein levels and abolished differences between GC-
sensitive and GC-resistant cells, suggesting that BAG-1 mediated proteasomal
degradation of GR accounts in part for the human variability in endothelial sen-
sitivity to GCs [131]. In vivo, proteasome inhibition improved GC sensitivity
of endothelium and protected against brain edema [135].
Epigenetic mechanisms such as DNA methylation and histone modifica-
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tions also regulate GC sensitivity of endothelial cells. Dexamethasone-sensitive
and dexamethasone-resistant HUVECs have different GR promoter methyla-
tion patterns [136]. The GR gene contains several variants of the untrans-
lated exon 1: 1A–1I [137]. Each of these variants has its own promoter.
Dexamethasone-sensitive cells show higher methylation levels of promoter 1D
and lower methylation levels of promoter 1F. Pharmacological demethylation
with 5-aza-2-deoxycytidine increased the mRNA expression of all isoforms (ex-
cept 1D in resistant HUVECs) and enhanced the GC sensitivity [136]. An-
other epigenetic mechanism that influences endothelial GC sensitivity involves
Sin3A-HDAC. This multi-protein complex that regulates gene expression via
histone deacetylation consists of SAP30, Sin3, histone deacetylases HDAC1
and HDAC2, histone binding proteins RbAp46 and RbAp48, and other pro-
teins. SAP30 represses gene transcription via tethering to gene promoters
[138]. Poor expression of Sap30 has been suggested as an explanation of im-
paired transrepression in HUVECs [139]. Transgenic overexpression of SAP30
in HUVECs and analysis of its expression under inflammatory conditions would
also improve the current understanding of how GC sensitivity is regulated in
endothelium.
Variations in the expression of the GC-activating and -deactivating enzymes
11β-HSD1 and 11β-HSD2 have been described in endothelial cells [140]. How-
ever, it remains unclear to what extent this affects the GC sensitivity.
In conclusion, the currently known mechanisms regulating GC sensitivity
in endothelial cells summarized in Figure 3 include proteasomal degradation
of GR and epigenetic modifications. However, the mechanisms that control
GC sensitivity are complex and often cell-type specific. The regulation of GC
sensitivity in endothelial cells has not yet been sufficiently addressed, in partic-
ular under inflammatory conditions. Since endothelium plays a crucial role in
inflammation, we believe that further studies on this subject will open up new
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perspectives for the development and improvement of the current treatment
strategies.
GCs sensitivity of endothelium ↓
Low SAP30
expression
methylation of GR promoter variants
GR association with BAG1 and GR proteasomal degradation
Figure 3: Proteasomal degradation and epigenetic modifications regulate
GC sensitivity in endothelial cells. Proteasomal degradation of GR impairs
GR activity and prevents physiological actions of GCs. In dexamethasone-
resistant HUVECs, GR associates with the proteasomal recruiting protein
BCL2-associated athanogene 1 (BAG1). This results in a shorter half-life of
GR. In HUVECs low induction of SAP30 (component of Sin3A-histone deacety-
lase complex) impairs GR-mediated transrepression and leads to lower GC
sensitivity. Furthermore, higher methylation of the promoters of the differ-
ent variants of the untranslated exon 1 of GR leads to lower expression and
therefore decreased GC sensitivity.
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1.7 Specific aims
Previously, our group developed a mouse model of MA-ARDS with C57BL/6
mice infected with P. berghei NK65. These mice develop MA-ARDS with
increased vascular permeability, protein-rich lung edema and leukocyte infil-
tration. According to the observed histopathology, this mouse model exhibits
important similarities to human MA-ARDS and is suitable to investigate both
pathogenesis and therapeutic strategies [2]. In this model, extremely high doses
of GCs (80 mg/kg) blocked development of MA-ARDS but failed to inhibit the
expression of pro-inflammatory molecules in the lungs of infected mice. The
highest doses acceptable in the clinic (3 mg/kg) did not prevent the pathology
and failed to decrease the pulmonary expression of cytokines and chemokines.
This suggests that malaria decreases GC sensitivity [8]. However, the mecha-
nisms underlying GC resistance in MA-ARDS remain unknown. The general
aim of this thesis was to identify molecular mechanisms of GC resistance in
MA-ARDS. To this end, 3 specific steps were taken:
1. to establish an in vitro model of malaria induced GC resistance. Since this
PhD project aimed to investigate the molecular mechanisms of malaria-
induced GC resistance, we searched for a simple model with one cell type.
In view of the importance of endothelium in malaria, I stimulated mouse
lung endothelial cells with IFN-γ and P. berghei NK65 and investigated
their GC sensitivity.
2. to study the GR signaling in mouse lung endothelial cells challenged with
IFN-γ and malaria parasites in the presence or absence of GCs. Impaired
GR signaling has been reported as one of the mechanisms underlying
GCs resistance in various diseases. Therefore, I first investigated GR
phosphorylation and nuclear translocation.
3. to evaluate the effects of GCs on STAT1 and MAPK signaling in mouse
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lung endothelial cells challenged with IFN-γ and malaria parasites. IFN-γ
activates two pro-inflammatory signaling pathways, STAT1 and MAPK.
GCs have been shown to regulate both pathways in various experimental
models. As a next step, I studied the effects of GCs on STAT1. Moreover,
I also investigated the effects of specific MAPK inhibitors on the induction
of inflammatory chemokines and the effects of GCs on MAPK signaling.
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2 Development of an in vitro model of malaria-
induced GC resistance
2.1 Introduction
Chemokines and cytokines regulate leukocyte migration during malaria and
contribute to the pathogenesis of severe malaria. Increased levels of CXCL8
(IL-8) and CXCL9 (MIG) have been observed in patients with severe malaria.
Furthermore, CXCL10 (IP-10) has been used as a biomarker for P.falciparum-
induced cerebral malaria [141, 142]. In contrast, low levels of CCL5 (also known
as regulated on activation, normal T cell expressed and secreted (RANTES))
in children with cerebral malaria correlate with mortality [143]. In the mouse
model of cerebral malaria, upregulation of several chemokines, such as CXCR3
ligands have also been observed. CXCL9 (MIG) and CXCL10 (IP-10) were
mainly expressed in cerebral microvessels and in adjacent glial cells, whereas
CCL5 (RANTES) was predominantly produced by infiltrating lymphocytes.
CXCR3 KO mice were protected from cerebral malaria and showed less CD8+T
cells in the brain [144]. CXCL10 (IP-10) deficiency has been shown to protect
against cerebral malaria and to reduce parasite biomass in vivo [142].
IFN-γ plays an important role in controlling both the liver and the blood
stage of malaria [145, 146, 147]. However, it can also aggravate malaria infec-
tions. For example, IFN-γ has been shown to exacerbate the pathology in ani-
mal models of cerebral malaria [145, 148]. IFN-γ synergizes with lymphotoxin-α
and TNF to induce the expression of adhesion molecules (E-selectin and ICAM-
1) [28]. Moreover, IFN-γ produced by CD4+T cells upregulates CXCL9 (MIG)
and CXCL10 (IP-10) in endothelial cells and induces CD8+T cell recruitment
into the brain [149, 150]. IFN-γ KO mice are protected from cerebral malaria
and show lower leukocyte infiltration in the brain [151]. Similarly, in the IFN-
γR1 KO mice infected with PbANKA leukocyte infiltration into the brain was
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absent. However, leukocyte infiltration into the lungs was still observed in
the KO mice. WT and KO mice also showed specific patterns of chemokine
and chemokine receptor expression. Induction of CCL5 (RANTES), CXCL10
(IP-10) and CCR2 was associated with leukocyte infiltration into the brain,
whereas upregulation of CCL2 (MCP-1), CXCL10 (IP-10) and CCR5 was as-
sociated with leukocyte migration into the lungs [152]. Interestingly, CXCR3
KO mice produce less IFN-γ and lymphotoxin-α in the brain [144].
In this chapter, I stimulated mouse lung endothelial cells (L2 MVECs) with
IFN-γ and IFN-γ in combination with malaria parasites and evaluated their GC
sensitivity. As a readout for GC sensitivity, I analyzed the effects of GCs on the
induction of several chemokines such as CXCL10 (IP-10), CCL5 (RANTES)
and CCL2 (MCP-1), which play an important role in malaria.
2.2 Materials and methods
2.2.1 Cell cultures
The murine lung microvascular endothelial cell line (L2 MVEC, a kind gift
from Dr J. Brian De Souza, London School of Hygiene and Tropical Medicine)
was cultured in RPMI medium (Gibco, Belgium) supplemented with 2 mM
L-glutamine (Gibco), 0.1 mg/mL streptomycin (Sigma, Belgium), 200 U/mL
penicillin (Kela, Belgium) and 10% FCS (Gibco). Cells were grown in 5% CO2
at 37°C.
2.2.2 Mice
All animal experiments were performed in accordance to the regulations as de-
clared in Directive 2010/63/EU from the European Union and and the Belgian
Royal Decree of 29 May 2013 and were approved by the Animal Ethics Com-
mittee from the KU Leuven (project number P163-2014, License LA1210186,
Belgium). All efforts were made to minimize suffering of animals. Unless oth-
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erwise indicated, male Balb/c mice were obtained from Janvier (seven to eight
weeks old, Le Genest-Saint-Isle, France). Mice were injected intraperitoneally
with 106 PbNK65-infected RBCs (a kind gift of the late Prof. D. Walliker,
University of Edinburgh). Mice were kept in a conventional animal house and
drinking water was supplemented with 4-amino benzoic acid (0.375 mg/ml,
PABA, Sigma-Aldrich, Bornem, Belgium). Parasitemia was determined by mi-
croscopic analysis of blood smears of tail blood after Giemsa staining (1/10
dilution, VWR, Heverlee, Belgium). Mice were sacrificed 8 days after infection
(when parasitemia was approximately 4%) by euthanasia with Dolethal (Vto-
quinol, Aartselaar, Belgium; 200 mg/ml, intraperitoneal injection of 50 µl) and
cardiac punctures were performed.
2.2.3 Ex vivo cultivation of PbNK65 and extract production
After cardiac punctures blood was filtered with Plasmodipur filters (Europrox-
ima) to remove leukocytes and washed with RPMI medium (Gibco) supple-
mented with: 25 mM HEPES, 0.425 g NaHCO3, 2 mM L-glutamine (Gibco), 5
mM glucose (Sigma) and 20% FCS. The pellet was resuspended and seeded into
culture flasks. Cells were gassed with a mixture of 92.5% N2, 5.5% CO2, 2%
O2 and cultured overnight at 37°C. The next day the culture was centrifuged,
resuspended in RPMI medium and loaded on MACS column (Miltenyi Biotec,
NL) to purify the schizonts on the basis of their inherent magnetic proper-
ties. After elution the schizonts were diluted to the concentration of 108/mL
in RPMI medium, aliquoted and frozen at -20°C. Next they were thawed and
frozen at -20°C again to produce the extract.
2.2.4 Stimulation of L2 MVECs with IFN-γ , PbNK65 extract
and cytokine determination
L2 MVECs were seeded in 6, 24, 48 or 96 well plates at the concentration of
5·104 cells/mL. After expanding the cells for 24 hours, they were washed with
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medium and stimulated for 24 hours with combinations of murine IFN-γ (20
ng/mL, PeproTech, USA), parasite extract (107 infected RBCs – iRBCs/mL),
murine RBCs extract (107 RBCs/mL), and dexamethasone (100 nM final con-
centration, diluted form a stock solution of 0.06M dissolved in DMSO, Sigma).
After stimulation plates were centrifuged (5 minutes, 1200 rpm, RT) and super-
natants were collected for ELISA and stored at -20°C. Cytokines were analyzed
by ELISA (R&D).
2.2.5 Quantitative RT-PCR and RNA-seq
Cells were washed with PBS, lysed using RLT buffer with β-mercaptoethanol
from the RNeasy Mini kit (Qiagen, Belgium) and stored at -80°C for RNA ex-
traction. RNA was extracted with RNeasy Mini Kit (Qiagen) according to the
manufacturer’s protocol. RNA concentration and purity were evaluated with
Nanodrop 1000 (Thermo Scientific, Belgium). RNA (0.25µg) was converted
to cDNA using high-capacity cDNA reverse transcription kit (Applied Biosys-
tems). Quantitative RT-PCR was performed with 6.25 or 0.125 ng cDNA using
predesigned primers (IDT) and TaqMan Universal PCR Master Mix (Applied
Biosystems), respectively. RNA-Seq expression profiling was performed by the
Genomics Core UZ Leuven. Per independent experiment RNA from 3 technical
replicates per experimental condition was pooled and 3µg RNA/experimental
condition were sequenced from a total of 3 independent experiments. Illumina
TruSeq stranded mRNA kit was used and the single-end sequencing was per-
formed. 33M 50 bp reads per sample were sequenced. Reads were aligned to
mm10 murine genome using TopHat. A heatmap with highly variable genes
across the samples was plotted using pheatmap package (pheatmap). The rlog
transformed counts of each gene were centered across the samples. Ribosomal
RNA genes and predicted genes that were increased in one sample (GC027190)
were excluded from the rlog data used for heatmap since this increase was
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a result of an imperfect poly-A selection during the library preparation of this
sample. Differential expression analysis was performed with DESeq2 [153].
Differences in gene expression with a FDR adjusted p value below 0.1 were
considered significant. Gene ontology analysis of differentially expressed genes
was performed with clusterProfiler package [154]. Motif analysis of the prox-
imal promoter region (400bp upstream of the transcription start site till 100
bp downstream) was performed using Homer software (Homer motif analysis).
RNA-seq data were submitted to ArrayExpress (accession number E-MTAB-
5921, (ArrayExpress URL)).
2.3 Results
2.3.1 Lung endothelial cells remain GC sensitive upon stimulation
with IFN-γ
IFN-γ plays a crucial role in the induction of chemokines in mouse models of
complicated malaria [145, 150]. To evaluate if IFN-γ might cause GC resistance
in lung endothelial cells, we stimulated L2 MVECs with IFN-γ in the presence
or absence of dexamethasone for 24 hours. IFN-γ induced CCL2 (MCP-1),
CXCL10 (IP-10), and CCL5 (RANTES) on both protein and RNA levels (Fig-
ure 4). CXCL10 (IP-10) showed the strongest induction. Dexamethasone in-
hibited IFN-γ-induced chemokine secretion, suppressing CCL5 (RANTES) by
90% and both CXCL10 (IP-10) and CCL2 (MCP-1) approximately by 50%
(Figure 4a). Real-time qPCR experiments revealed 90% inhibition of CCL5
(RANTES) and 71% inhibition of both CXCL10 (IP-10) and CCL2 (MCP-
1). Moreover, treatment with dexamethasone (with or without IFN-γ) induced
MKP-1 (DUSP1), GILZ (Tsc22d3) and FKBP51 (Figure 7), indicating that
IFN-γ did not alter GC-mediated transactivation of these genes. These results
indicate that IFN-γ-stimulated lung endothelial cells remain GC sensitive.
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(a)
(b)
Figure 4: Dexamethasone inhibits pro-inflammatory chemokine secretion in
lung endothelium stimulated with IFN-γ. L2 MVECs were treated with vehi-
cle (con) or IFN-γ (20 ng/mL) in the presence or absence of dexamethasone
(Dex, 100 nM) for 24 hours. CCL2 (MCP-1), CXCL10 (IP-10) and CCL5
(RANTES) expression levels were analyzed by ELISA (a) and real-time qPCR
(b). Statistical significance was evaluated using ANOVA (*** p <0.001). Data
show combined results from 3 independent experiments.
2.3.2 GCs differentially affect the transcriptional response to IFN-γ
in lung endothelial cells
To further characterize the transcriptional targets indicating GC sensitivity
in lung endothelial cells, we analyzed by RNA-seq the transcriptome of L2
MVECs in 4 different conditions: unstimulated control, stimulated with dex-
amethasone alone, stimulated with IFN-γ alone, stimulated with IFN-γ and
dexamethasone. IFN-γ induced expression of various guanylate binding pro-
teins (GBPs), which trigger antimicrobial effector mechanisms via inhibition of
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replication of intracellular pathogens (Figure 5a) [155]. Similarly, we found sev-
eral interferon-induced proteins with tetratricopeptide repeats (IFITs). These
proteins inhibit viral replication [156]. IFN-γ also increased expression of H-
2 class II histocompatibility genes and adhesion molecules such as VCAM-1
and ICAM-1. Moreover, IFN-γ potently induced transcription of various pro-
inflammatory CXC and CCL chemokines including CXCL9 (MIG), CXCL11
(MIG), CXCL10 (IP-10), CCL5 (RANTES) and CCL2 (MCP-1, Figure 5a).
These data on chemokine induction further confirm the ELISA and qRT-PCR
experiments shown in Figure 4.
Dexamethasone significantly inhibited large clusters of genes induced by
IFN-γ, which included several CXC and CCL chemokines (Table 1). In partic-
ular, dexamethasone markedly diminished transcription of CCL5 (RANTES,
more than 85% reduction), CXCL11 (MIG, more than 80% reduction), CCL4
and CCL3 (more than 75% reduction, Figure 5b). Also, IFN-γ-induced in-
terleukin 1β (IL-1β), IL-27 and IFITs were downregulated by dexamethasone.
In contrast, the expression of GBPs, STAT family members and the cytokine
IL-15 was resistant to GC-mediated transcriptional inhibition (Table 1).
In addition, we found a large cluster of genes upregulated by GCs. Dexam-
ethasone induced several anti-inflammatory genes in IFN-γ-stimulated endothe-
lial cells including orosomucoid-1 (Orm1, Fold Change 11.3), DEP domain-
containing mTOR-interacting protein (DEPTOR, Fold Change 5.3) and GILZ
(Tsc22d3, Fold Change 4.6, Figure 5c) – a known GR target gene. These genes
were also upregulated upon treatment with dexamethasone alone. Interest-
ingly, another set of genes was repressed by IFN-γ alone, but the expression
was restored when dexamethasone was added. These genes include CXCL12,
angiopoietin-like protein (Angptl)7, TGF-β2, TLR7 and tumor necrosis factor
receptor superfamily member (TNFRSf)21. Altogether, these data indicate
that lung endothelial cells are GC sensitive, when stimulated with IFN-γ.
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As for the affected pathways, gene ontology (GO) analysis of genes induced
by IFN-γ at least 2 fold and inhibited by dexamethasone at least by 50% (Fig-
ure 5d) revealed a high prevalence of biological process GO terms related to
regulation of immune response and pro-inflammatory signaling pathways such
as MAPK (Figure 5e). Several binding partners have been involved in GR-
mediated repression of pro-inflammatory genes including AP-1, NF-κB and
interferon regulatory factor (IRF)3 [69, 157, 158]. Interestingly, a computa-
tional analysis of the 400-bp region upstream of genes induced by IFN-γ at
least 2 fold and inhibited by dexamethasone at least by 50% showed a sig-
nificant enrichment of the binding sites for IRF and NF-κB families but not
for GR (Table 2). These results remain in line with previous findings since
in LPS-stimulated macrophages, less than 6% of GR binding sites occurred at
proximal promoter regions [158]. Also, GR can tether to DNA-bound TFs such
as NF-κB without requiring a GRE motif.
2.3.3 PbNK65 extract in combination with IFN-γ induces GC re-
sistance in lung endothelium
Although GC resistance has been observed in our murine model of MA-ARDS
[8], the above results indicate that IFN-γ-stimulated lung endothelial cells re-
main GC sensitive. As sequestering parasites release a variety of products which
can further activate endothelial cells [10, 11], we investigated whether addition
of parasite extract might alter the GC sensitivity of L2 MVECs. PbNK65 ex-
tract in combination with IFN-γ increased the mRNA levels of CCL2 (MCP-1)
and CCL5 (RANTES) respectively 2-fold and 3-fold in comparison to IFN-γ
alone (Figure 6a). PbNK65 alone increased only CCL2 (MCP-1) protein levels
and interestingly, this induction was sensitive to dexamethasone (Figure 6b).
Importantly, dexamethasone failed to inhibit mRNA and protein induction of
CCL2 (MCP-1), CCL5 (RANTES) and CXCL10 (IP-10), when cells were chal-
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Gene
symbol
IFN-γ vs
con Log2FC
IFN-γ+Dex vs
IFN-γ Log2FC
CXCL16 2.4 -1.2
CXCL14 -1.7 0.75
CXCL12 -0.8 1.2
CXCL11 7.5 -2.6
CXCL10 7.4 -1.6
CXCL9 9.7 -1.6
CXCL5 NS -1.4
CXCL1 NS -1.2
CCL27a 0.8 NS
CCL22 3.9 -2
CCL20 1.4 -1.5
CCL17 NS -1
CCL12 3.8 -1.4
CCL11 1.9 NS
CCL9 -1.3 0.9
CCL8 3.3 -0.9
CCL7 1.6 -1.4
CCL6 1.2 NS
CCL5 6 -3.1
CCL4 2.4 -2.2
CCL3 1.1 -2.2
CCL2 2.2 -1.6
IL-34 NS -1.1
IL-33 -1.5 NS
IL-27 3.4 -1.8
IL-18 0.6 0.6
IL-15 2.4 -0.5
IL-10 1.4 1.4
IL-7 1.2 NS
IL-6 0.8 -1.6
IL-1α 2.5 -1.6
IL-1β 4.2 -2.5
TNF 2.2 -1.6
TNFSF18 1 NS
TNFSF15 2.1 -1.6
TNFSF13b 2.8 NS
TNFSF11 -0.8 NS
TNFSF8 -1.3 NS
Table 1: Differentially expressed chemokines and cytokines in lung endothelial
cells stimulated with IFN-γ in the presence or absence of dexamethasone (FC
– fold change, NS – non-significant).
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Rank Motif / Name p-value q-value % of target
sequences
with motif
1 TCAGTCAGGCTACGTATACGGACTTCAGTCGACTGACGTATACGGACT
IRF8(IRF)/BMDM-IRF8-
ChIP-Seq(GSE77884)
1e−13 < 1e−4 40.26%
2 CTG
A
T
A
C
G
G
C
A
T
A
G
C
T
A
G
C
T
A
G
T
C
T
C
G
A
A
C
T
G
C
A
G
T
AGC
T
AG
C
T
GA
T
C
IRF3(IRF)/BMDM-Irf3-ChIP-
Seq(GSE67343)
1e−13 < 1e−4 36.36%
3 TCAGCTGACGTACGTATACGGCATCTAGCTGACGTACGTATACGGACT
IRF1(IRF)/PBMC-IRF1-ChIP-
Seq(GSE43036)
1e−11 < 1e−4 25.97%
4 CTAGCTAGCGTACGTATACGCGATCTAGCTGACTGACGTATACGGACT
PU.1:IRF8(ETS:IRF)/pDC-
Irf8-ChIP-Seq(GSE66899)
1e−9 < 1e−4 27.27%
5 CTG
A
A
T
C
G
AGCTAGCTACGTTAGCCTGATACGCGATACGTGACTAGTC
ISRE(IRF)/ThioMac-LPS-
Expression(GSE23622)
1e−8 < 1e−4 15.58%
6 TGA
C
CT
A
G
TC
A
G
GT
CA
CGT
A
T
C
A
G
C
G
A
T
TC
A
G
T
C
G
A
T
G
C
A
C
T
G
A
T
A
G
C
PU.1-IRF(ETS:IRF)/Bcell-
PU.1-ChIP-Seq(GSE21512)
1e−7 < 1e−4 63.64%
7 TCGATGACGCATAGCTCAGTGATCGCTAGATCGACTACGTGCATAGTC
PRDM1(Zf)/Hela-PRDM1-
ChIP-Seq(GSE31477)
1e−7 < 1e−4 35.06%
8 CTA
G
T
C
G
A
C
T
G
A
C
G
T
A
T
A
C
G
G
A
C
T
T
C
A
G
T
C
G
A
G
T
C
A
T
G
C
A
T
A
C
G
A
G
C
T
IRF2(IRF)/Erythroblas-IRF2-
ChIP-Seq(GSE36985)
1e−4 0.0013 14.29%
9 ACTGCATGGCTATCGAGCTAAGCTAGCTGTACAGTCTGAC
NFkB-p65-Rel(RHD)/ThioMac-
LPS-Expression(GSE23622)
1e−4 0.0014 10.39%
10 CGT
A
CA
T
G
CAT
G
ACT
G
CT
A
G
T
C
G
A
G
C
A
T
C
G
A
T
AGC
T
AGT
C
GAT
C
G
T
A
C
NFkB-p65(RHD)/GM12787-
p65-ChIP-Seq(GSE19485)
1e−3 0.004 28.57%
Table 2: Top 10 enriched transcription factor-binding motifs in -400 to +100
bp in genes induced by IFN-γ at least 2 fold and repressed by dexamethasone
at least by 50%.
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lenged with the combination of PbNK65 extract and IFN-γ (Figure 6a and 6b).
These results indicate that PbNK65 extract impairs GC-mediated transrepres-
sion of these inflammatory chemokines observed after stimulation with IFN-γ
alone. In contrast, PbNK65 extract failed to affect GC-induced transactivation
of MKP-1 (DUSP1), GILZ (Tsc22d3) and FKBP51 (Figure 7).
To evaluate the time course of the development of GC resistance, we stim-
ulated lung endothelial cells with PbNK65 extract and IFN-γ for 6, 24 and 48
hours in the presence or absence of dexamethasone and analyzed CCL2 (MCP-
1) and CXCL10 (IP-10) secretion. After 6 hours chemokine levels remained
low both in the resistant condition with PbNK65 extract and IFN-γ and in
the sensitive one with IFN-γ alone (Figure 8). GC resistance for CCL2 (MCP-
1) occurred following 24 hour stimulation with PbNK65 extract and IFN-γ
and was still present after 48 hours. PbNK65 extract and IFN-γ induced GC
resistance for CXCL10 (IP-10) already after 6 hours. Notwithstanding these
gene-specific differences in kinetics, all studied genes underwent GC resistance
upon combining IFN-γ with PbNK56 extract. In contrast, upon stimulation
with IFN-γ alone endothelial cells remained fully GC sensitive even after 48
hours.
As a control for the PbNK65 extract, we stimulated lung endothelial cells
with extract from non-infected RBCs and evaluated GC sensitivity. RBC ex-
tract did not induce CCL2 (MCP-1) or CXCL10 (IP-10) in endothelial cells (Fig-
ure 9). When combined with IFN-γ, RBC extract failed to enhance secretion
of pro-inflammatory chemokines. Furthermore, dexamethasone inhibited CCL2
(MCP-1) and CXCL10 (IP-10) production induced by IFN-γ in the presence of
RBC extract, showing that RBC extract is not able to induce GC resistance.
These results confirm that parasite components but not RBC components me-
diate GC resistance.
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2.4 Discussion
Changes to the microvasculature are among the hallmarks of malaria pathol-
ogy. IFN-γ synergizes with lymphotoxin-α and TNF to induce the expression of
adhesion molecules (E-selectin and ICAM-1) in brain endothelial cells [28]. In
line herewith, our RNA-Seq analysis in lung endothelial cells showed that IFN-
γ induces transcription of VCAM-1 and ICAM-1. Dexamethasone significantly
inhibited expression of these adhesion molecules. Moreover, dexamethasone in-
duced protective molecules including anti-inflammatory factors and junctional
proteins.
Several cytokines have been shown to induce GC resistance in various cell
types. In human bronchial epithelial cells, pre-incubation with IL-17A impairs
the inhibitory effect of GCs on TNF-induced IL-8 via PI3K activation and
subsequent reduction of HDAC2 activity. However, IL-17A lacks effect on
GR-mediated transactivation [159]. In contrast, TGF-β impairs GR-mediated
induction of anti-inflammatory genes in A549 cells [160]. IL-13 has been shown
to decrease GR ligand binding affinity in monocytes [161]. In PBMCs, IL-17
and IL-23 cause GC resistance in PBMCs via induction of GRβ [162]. Also,
IL-2 might cause GC resistance in PMBCs [163]. In eosinophils IL-2 and IL-4
as well as TNF and IFN-γ, or IL-3, granulocyte-macrophage colony-stimulating
factor (GM-CSF), and IL-5 alone diminish GC-induced apoptosis and therefore
cause GC resistance. IL-2 and IL-4 impair GR phosphorylation. Impaired GR
phosphorylation correlates with increased protein phosphatase 5 (PP5) activity
and PP5 silencing restores GC sensitivity [164].
The involvement of IFN-γ in GC resistance has been extensively stud-
ied [165, 166]. In the present study, we show that lung endothelial cells re-
main GC sensitive upon challenge with IFN-γ. However, combined treatment
with IFN-γ and PbNK65 extract impairs GC-mediated inhibition of the pro-
duction of pro-inflammatory cytokines. IFN-γ has been shown to induce GC
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resistance in other disease models in combination with bacterial products or
cytokines. For example, cooperative signaling between IFN-γ and LPS induces
IL-27 in mouse macrophages and inhibits GR nuclear translocation [165]. In
airway smooth muscle cells, treatment with IFN-γ and TNF causes GC re-
sistance. Short term stimulation with IFN-γ and TNF impairs GR binding
to DNA and GRE-dependent transcription via upregulation of GRβ, whereas
long term treatment depletes GRIP-1 from the GR transcriptional regulatory
complexes [166, 167, 168]. In contrast, Goleva and colleagues showed that IFN-
γ reverses GC resistance induced in T cells by long term treatment with IL-2
and IL-4 [169].
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Figure 5: GCs diminish transcriptional activity induced by IFN-γ. Genome wide ex-
pression was measured (n=3), log2FoldChange has been depicted including standard
error estimate (lfcSE, error bars). (a) Top 30 genes activated by IFN-γ in endothelial
cells. (b) Top 30 genes down-regulated by dexamethasone in endothelial cells stimu-
lated with IFN-γ. (c) Top 30 genes induced by dexamethasone in IFN-γ-stimulated
endothelial cells. (d) Venn diagram depicts overlap between genes induced by IFN-γ
and repressed by dexamethasone (e) Biological process GO analysis (top 30 terms) of
genes induced at least two fold by IFN-γ and repressed at least 50% by dexametha-
sone.
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(a)
(b)
Figure 6: PbNK65 extract in combination with IFN-γ induces GC resistance in
lung endothelial cells. L2 MVECs were treated with vehicle (con), IFN-γ (20
ng/mL), PbNK65 extract or IFN-γ and PbNK65 extract (PbNK65, 107 infected
RBCs/mL) in the presence or absence of dexamethasone (Dex, 100 nM) for 24
hours. CCL2 (MCP-1), CXCL10 (IP-10) and CCL5 (RANTES) levels were
analyzed by real-time qPCR (a) and ELISA (b). Statistical significance was
evaluated using Mann-Whitney test (** p <0.01, *** p <0.001). Data represent
combined results from at least 2 independent experiments.
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Figure 7: Dexamethasone induces MKP-1 (DUSP1), FKBP51 and GILZ in
IFN-γ or IFN-γ and PbNK65-treated lung endothelial cells. L2 MVECs were
stimulated with vehicle (con), IFN-γ (20 ng/mL) or IFN-γ and PbNK65 extract
(PbNK65, 107 infected RBCs/mL) in the presence or absence of dexamethasone
(Dex, 100 nM) for 24 hours. MKP-1 (DUSP1), FKBP51 and GILZ expression
was analyzed by qRT-PCR. Statistical significance was evaluated using ANOVA
(* p <0.05, ** p <0.01, *** p <0.001). Data represent combined results from
at least 3 independent experiments.
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(a) (b)
(c) (d)
Figure 8: PbNK65 extract in combination with IFN-γ induces GC resistance
after 6 or 24 hours. L2 MVECs were stimulated with vehicle (con), IFN-γ (20
ng/mL) and IFN-γ and PbNK65 extract (PbNK65, 107 infected RBCs/mL) in
the presence or absence of dexamethasone (Dex, 100 nM). CCL2 (MCP-1) and
CXCL10 (IP-10) levels in culture supernatant were analyzed by ELISA. Data
are presented as mean of 2 independent experiments +/- SD.
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Figure 9: Murine RBC extract exhibits no effect on cytokine induction and
GC sensitivity of lung endothelial cells. L2 MVECs were stimulated with ve-
hicle (con), IFN-γ (20 ng/mL), RBC (107 RBCs/mL), RBC and IFN-γ in the
presence or absence of dexamethasone (Dex, 100 nM) for 24 hours. CCL2
(MCP-1) and CXCL10 (IP-10) production was analyzed by ELISA. Statisti-
cal significance was evaluated using ANOVA (*** p <0.001). Data represent
combined results from 2 independent experiments.
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3 PbNK65 and IFN-γ do not impair GR phos-
phorylation and translocation in lung endothe-
lial cells
3.1 Introduction
In the previous chapter, I showed that L2 MVECs remain GC sensitive upon
stimulation with IFN-γ, but they become GC resistant when IFN-γ is combined
with the parasite extract. In this chapter, the mechanism underlying this GC
resistance is investigated. The nuclear translocation of GR, which is regulated
by phosphorylation, is crucial for GR activity and is often impaired under GC
resistant conditions [127].
Ligand binding induces GR phosphorylation (with the exception of serine
150 threonine 159) and therefore GR represents a target for various kinases
[170]. For example, cyclin dependent kinase (CDK) complexes and MAPK
have been shown to mediate GR phosphorylation. In rats, CDK complexes
phosphorylate serine 224 and 232, whereas MAPK modify threonine 171 and
serine 246. CDK-mediated phosphorylation is required for full transcriptional
activity of GR. In contrast, MAPK-induced phosphorylation of threonine 171
and serine 246 reduces GR transcriptional activity of GR [171]. Interestingly,
p38 MAPK has also been shown to induce serine 211 (S211) phosphorylation of
GR and GC-mediated apoptosis in lymphoid cells [172]. S211 phosphorylation
correlates with transcriptional activity of GR. Phosphorylated S211 has also
been used as a biomarker for activated GR since phosphorylated S211 GR
mainly localizes in the nucleus [173]
JNK, another member of MAPK family, has been shown to phosphorylate
GR at S246. Activation of JNK attenuates GR transcriptional activity, provid-
ing a means to terminate GR-mediated transcription when it interferes with
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pro-inflammatory signals [174]. Moreover, activated JNK also phosphorylates
GR on Serine 226 and enhances GR nuclear export leading to termination of
GR transcriptional activity [175]. In this chapter, we investigated the S211
and S226 GR phosphorylation and GR nuclear translocation in lung endothe-
lial cells stimulated with IFN-γ, IFN-γ and PbNK65 in the presence or absence
of dexamethasone.
3.2 Materials and methods
3.2.1 Western blot
For Western blot analysis protein extracts from L2 MVECs stimulated with
IFN-γ, PbNK65 extract, IFN-γ and PbNK65 extract in the presence or absence
of dexamethasone were separated on SDS PAGE gels and blotted onto a PVDF
membrane. Blocking was performed with BSA (Carl Roth Gmbh, Belgium) or
non-fat dry milk (Bio Rad, USA). The following primary Ab were used p-GR
S211 (1:1000, Cell Signaling Technology), p-GR S226 (1:1000, Abcam), GR
H300 (1:1000, Santa Cruz, Germany). Fusion solo S system (Vilber, France)
was used to produce chemiluminescence Western blot images. Quantification
of Western blot images was performed by densitometry (ImageJ software was
used).
3.2.2 GR nuclear translocation
Cells were seeded on coverslips and incubated in phenol-red-free and serum-free
medium for 4h. Cell fixation, methanol permeabilization and staining were
performed according to Cell Signaling guidelines. GR was visualized with the
GR polyclonal (H300) antibody (Santa Cruz, Germany), used at 1:200, followed
by probing with Alexa Fluor 488 (Invitrogen, Belgium). Nuclei were visualized
using 4’,6-diamidino-2-phenylindole (DAPI) staining. A motorized inverted
IX81 FluoView FV1000 laser scanning confocal microscope (Olympus) was used
41
to record high-resolution images. Assessment of intracellular localization of
protein signal was done double-blind.
3.3 Results
3.3.1 PbNK65/IFN-γ cotreatment preserves homologous GR down-
regulation and GR nuclear translocation
GR undergoes homologous downregulation when incubated with its ligand for
longer periods of time. Perturbations of this process may lead to GC resis-
tance [176, 177]. To evaluate the levels of GR, we stimulated L2 MVECs for 6
or 24 hours with vehicle (DMSO), RBC extract, IFN-γ, PbNK65 extract, IFN-
γ and PbNK65 extract in the presence or absence of dexamethasone. The levels
of GR remained unchanged in the resistant condition with IFN-γ and PbNK65
extract when compared to the sensitive condition with IFN-γ alone. Addition-
ally, the capacity and extent of GC-induced GR homologous downregulation
remained unaffected in either the sensitive or resistant condition. We also
investigated the S211 phosphorylation of GR, since this modification is associ-
ated with transcriptionally active GR and provides a means for cross-talk with
other signaling pathways [178]. As expected, dexamethasone alone induced
S211 phosphorylation. Moreover, phosphorylation of GR at S211 remained
present when cells were challenged with IFN-γ or IFN-γ with PbNK65 extract
in the presence of dexamethasone (Figure 10a and 10b). We also evaluated
the GR S226 phosphorylation, which inhibits GR function [174, 175]. Dex-
amethasone inhibited GR S226 phosphorylation upon stimulation with IFN-γ
or IFN-γ with PbNK65 extract (Figure 10c). These data indicate that GC
resistance following IFN-γ/PbNK65 cotreatment is most likely not caused by
defective GR phosphorylation or GR homologous downregulation mechanisms.
Since impaired GR nuclear translocation leads to GC resistance [169, 127],
we assessed the ability of dexamethasone to induce GR translocation in lung
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endothelial cells. L2 MVECs were challenged for 24 hours with PbNK65 ex-
tract and IFN-γ and dexamethasone was added during the last hour of stimula-
tion (Figure 11). Immunofluorescence microscopy revealed that in unstimulated
cells GR localized mainly in the cytoplasm and translocated to the nucleus upon
dexamethasone exposure. GR also translocated to the nucleus upon treatment
with IFN-γ and dexamethasone. Furthermore, the translocation occurred in
the GC resistant condition with PbNK65 extract and IFN-γ (Figure 11). We
also obtained similar data for a shorter time point of 2 hours or with 24 hour
co-treatment with IFN-γ, PbNK65 extract and dexamethasone (Figure 12).
These data indicate that GC resistance is not caused by any defect in GR
translocation.
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(a)
(b)
(c)
Figure 10: IFN-γ and PbNK65 extract do not interfere with either GR ex-
pression or GR phosphorylation. (a, b, c) Western blot analysis of lysates of
L2 MVECs stimulated for 6 or 24 hours with solvent (DMSO), red blood cells
extract (RBC, 107 RBCs/mL), IFN-γ (20 ng/mL), PbNK65 extract (107 in-
fected RBCs/mL), IFN-γ and PbNK65 extract in the presence or absence of
dexamethasone (Dex, 100 nM).
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Figure 11: IFN-γ and PbNK65 extract preserve GR nuclear translocation in
lung endothelial cells. L2 MVECs were stimulated with solvent (con), IFN-γ
(20 ng/mL) or IFN-γ and PbNK65 extract (107 infected RBCs/mL) for 24
hours and treated for 1 hour with dexamethasone (100 nM). Endogenous GR
was visualized (green) through indirect immunofluorescence using anti-GR Ab.
DAPI staining (blue) indicates the nuclei of the cells.
Figure 12: IFN-γ and PbNK65 do not interfere with GR expression after 2
hours. L2 MVEC cells were stimulated with solvent (con), IFN-γ (20ng/mL)
or IFN-γ and PbNK65 extract (107 infected RBCs/mL) for 2 hours and treated
for 1 hour with dexamethasone (Dex, 100nM). Endogenous GR was visualized
(green) through indirect immunofluorescence using anti-GR Ab. DAPI staining
(blue) indicates the nuclei of the cells.
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3.4 Discussion
Various mechanisms leading to GC resistance have been proposed. We show
here that treatment with IFN-γ and PbNK65 extract, in the presence or absence
of GCs, affects neither GR levels nor GR S211 or S226 phosphorylation in lung
endothelial cells. GR S211 phosphorylation is associated with enhanced GR
activity whereas GR S226 phosphorylation exerts inhibitory effects on GR [170,
174, 175]. In contrast to our findings, several pro-inflammatory cytokines have
been shown to reduce GR levels or GR S211 phosphorylation. For example, IL-2
and IL-4 impair GR S211 phosphorylation in T cells [169]. TNF downregulates
the levels of hepatic GR in vivo and TGF-β exposure (before challenge with
IL-1α) reduces GR levels in A549 cells [179, 160]. However, TGF-β induced
by respiratory syncytial virus fails to downregulate GR levels in human airway
epithelial cells [180]. Proteasomal degradation of GR reduces its levels and was
proposed to cause GC resistance in endothelial cells [135, 136].
Impaired GR nuclear translocation represents another way to mediate GC
resistance in various models. In B cells, treatment with IL-4 and IL-15 inhibits
GR translocation [127]. Similarly, IL-4 and IL-2 impair GR translocation in T
cells [169]. Superantigens block GR translocation in PBMCs [181]. In contrast,
GR translocation remains functional in GC resistant HUVECs and lack of re-
sponse to GCs is associated with defects downstream of GR translocation [139].
This is in line with our data, since GR still translocated in the resistant condi-
tion with IFN-γ and PbNK65 extract. Moreover, IFN-γ and PbNK65 extract
did not affect mRNA levels of FKBP51 (Figure 7), which sequesters GR in the
cytoplasm and has been implicated in GC resistance [182, 183].
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4 Differential effects of GCs on STAT1 and
MAPK signaling in lung endothelial cells chal-
lenged with IFN-γ or PbNK65 and IFN-γ
4.1 Introduction
In this chapter, I investigated the effects of GCs on IFN-γ-induced signaling.
IFN-γ is a widely expressed cytokine that signals through the IFN-γ receptor
(IFNGR), which is composed of two subunits: IFNGR1 and IFNGR2 [184].
Each of the subunits associates with a specific member of the Janus activated
kinase (JAK) family. IFNGR1 interacts with JAK1 while IFNGR2 associates
with JAK2 [185]. The JAK-STAT signaling pathway was discovered as the
first pathway activated by IFNs. This pathway involves nuclear translocation
of STATs and induction of gene transcription. Upon IFN-γ binding to its
receptor, autophosphorylation of JAK1 and JAK2 occurs. Subsequently, JAK1
and JAK2 phosphorylate STAT1, which form homodimers and translocate to
the nucleus to activate gene transcription (Figure 13) [186].
IFN-γ has also been shown to activate the MAPK pathway (Figure 13) [187].
The mammalian family of MAPKs consists of extracellular signal-regulated ki-
nase (ERK), p38, and JNK. Each member of the MAPK family has several
isoforms: ERK1 to ERK8; p38-α,-β,-γ, and -δ; and JNK1 to JNK3 [188]. The
MAPK pathway is activated by sequential phosphorylation starting with phos-
phorylation of MAPK kinases (MAPKKs) by MAPK kinase kinases (MAP-
KKKs) [189]. MAPKs control various processes such as proliferation, differ-
entiation and survival and diverse stimuli can activate this pathway including
cytokines, hormones, growth factors and cellular stressors. Activated MAPKs
phosphorylate diverse target proteins including kinases, phosphatases, tran-
scription factors and cytoskeletal proteins [188]. Due to the role of MAPK in
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the regulation of essential cellular processes, this pathway has been implicated
in the development of various diseases such as cancer and neurodegenerative
diseases [190].
The ERK pathway is the best studied MAPK pathway and its activation
by growth factors and mitogens is relevant in cancer. Constitutive activation
of this pathway in cancer usually occurs at the early steps of the cascade.
Moreover, the activity of ERK target transcription factors such as myc and
AP-1 becomes amplified [188]. Both JNK and p38 are activated by cytokines
(for example TNF and IL-1β) and environmental stresses [190, 188, 191]. JNK1
and 2 are ubiquitously expressed whereas JNK3 is expressed only in heart,
brain and testis. JNK activation requires dual phosphorylation on tyrosine and
threonine residues. Upon activation, JNK and p38 translocate to the nucleus
and interact with their target transcription factors [188].
Since the MAPK pathway is activated by phosphorylation, dephosphory-
lation seems the most efficient way to switch off MAPK signaling. Several
phosphatases have been shown to inactivate MAPK pathway including ty-
rosine, serine/threonine and dual-specificity MAPK phosphatases (MKPs or
DUSPs). In mammals, at least ten MKPs have been described with MKP-1
(DUSP1) being the best studied member of MKP family. MKPs affect all as-
pects of immune response dependent on MAPK pathway, for example induction
of inflammatory mediators such as TNF, IL-1β, IL-6 and prostaglandin [192].
MKP-1 (DUSP1) plays a crucial role in the inhibition of JNK and p38 signaling
and attenuates inflammatory cytokine production in macrophages challenged
with LPS [193]. Similarly, MKP-1 (DUSP1) KO mice exhibit increased mor-
tality and cytokine production upon challenge with LPS. MKP-1 (DUSP1) KO
macrophages showed prolonged p38 activation and enhanced cytokine produc-
tion upon challenge with LPS [194].
IFN-γ has been shown to activate all members of MAPK pathway. In
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macrophages, IFN-γ stimulation results in strong activation of p38 at early
time points and weak activation of ERK and JNK at later time points. p38
is required for CCL5 (RANTES), CXCL9 (MIG), CXCL10 (IP-10) and TNF
induction [187]. Another study showed that IFN-γ activates the ERK path-
way and induces gene transcription dependent on C/EBP-B. Interestingly, this
transcription requires STAT1 but is JAK1 independent [195]. Matsuzawa and
colleagues identified a link between p38 signaling and autophagy induction by
IFN-γ in macrophages. In contrast, this induction is STAT1 independent [196].
To elucidate the mechanisms of the inhibitory actions of GCs on the IFN-
γ stimulated endothelial cells and to clarify the PbNK65-induced GC resistance,
the effects of GCs on the STAT1 and MAPK pathways were investigated.
4.2 Materials and methods
4.2.1 ELISA
Supernatants from L2 MVECs stimulated for 24 hours with the combina-
tions of murine IFN-γ (20 ng/mL, PeproTech, USA), parasite extract (107
infected RBCs/mL) and JNK, p38 and ERK inhibitors (SP600125, SB203580
and FR180204; R&D, UK, used at 20 µM, 5 µM and 10 µM, respectively) were
stored at -20°C. Cytokines were analyzed by ELISA (R&D) according to the
manufacturer’s protocol.
4.2.2 Western blot
For Western blot analysis protein extracts from L2 MVECs stimulated with
IFN-γ, PbNK65 extract, IFN-γ and PbNK65 extract in the presence or absence
of dexamethasone were separated on SDS PAGE gels and blotted onto a PVDF
membrane. Blocking was performed with BSA (Carl Roth Gmbh, Belgium) or
non-fat dry milk (Bio Rad, USA). The following primary Ab were used for
staining of JNK, pJNK, p38, p-p38 (1:2000, Cell Signaling Technology, The
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Figure 13: IFN-γ signals through STAT1 and MAPK pathways. IFN-γ binds a
cell-surface receptor called type II IFN receptor. This receptor consists of two
subunits, IFNGR1 and IFNGR2. Upon phosphorylation, STAT1 homodimer
translocates to the nucleus, binds to IFN-γ-activated site (GAS) and activates
gene transcription. Binding of IFN-γ to its receptor also induces small GT-
Pases to swap their GDP for a GTP. This results in MAPKKKs activation,
which activates MAPKKs. The last step of this cascade is MAPK activation.
Activated MAPKs translocate to the nucleus and phosphorylate target tran-
scription factors (TF) to induce gene expression.
Netherlands), p-STAT1 Tyr701 (1:1500, Cell Signaling Technology) and STAT1
(1:5000, Cell Signaling Technology). Fusion solo S system (Vilber, France)
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was used to take chemiluminescence Western blot images. Quantification of
Western blot images was performed by densitometry (ImageJ software was
used).
4.2.3 Quantitative RT-PCR
RNA was extracted with RNeasy Mini Kit (Qiagen) according to the manufac-
turer’s protocol. RNA concentration and purity were evaluated with Nanodrop
1000 (Thermo Scientific, Belgium). RNA (0.25µg) was converted to cDNA us-
ing high-capacity cDNA reverse transcription kit (Applied Biosystems). Quan-
titative RT-PCR was performed with 6.25 or 0.125 ng cDNA using predesigned
primers (IDT) and TaqMan Universal PCR Master Mix (Applied Biosystems),
respectively.
4.3 Results
4.3.1 Dexamethasone fails to inhibit STAT1 activation upon chal-
lenge with IFN-γ or PbNK65 extract and IFN-γ
Since STAT1 is involved in gene induction by IFN-γ, we evaluated the effect
of dexamethasone on STAT1 activation in the GC sensitive condition with
IFN-γ and in the resistant one with IFN-γ and PbNK65 extract. RNA-Seq
data showed that dexamethasone failed to affect STAT1 expression induced by
IFN-γ and this result was validated by qRT-PCR (Figure 14a). Since STAT1
phosphorylation at Tyr 701 controls STAT1 signaling, we subsequently ad-
dressed the impact of dexamethasone on phosphorylated STAT1. We showed
that STAT1 phosphorylation induced by IFN-γ remained unaffected by dex-
amethasone both in the GC sensitive (IFN-γ) and the GC resistant condition
(IFN-γ and PbNK65 extract, Figure 14b).
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(a) (b)
Figure 14: Dexamethasone failed to inhibit STAT1 expression or STAT1 phos-
phorylation induced by IFN-γ or IFN-γ and PbNK65 extract. (a) L2 MVECs
were stimulated with solvent (con) and IFN-γ (20 ng/ mL) in the presence or
absence of dexamethasone (Dex, 100 nM) for 24h. STAT1 expression was ana-
lyzed by qRT-PCR. Statistical significance was evaluated using Mann-Whitney
test. Data show combined results from 3 independent experiments. (b) Western
blot analysis of lysates of L2 MVECs stimulated for 6 or 24 hours with IFN-γ
(20 ng/mL), PbNK65 extract (107 infected RBCs/mL), IFN-γ and PbNK65
extract in the presence or absence of dexamethasone (Dex, 100nM) and red
blood cells extract (RBC, 107 RBCs/mL) was performed using anti-STAT1
and anti-pSTAT1 Ab.
4.3.2 IFN-γ and PbNK65 extract impair GC-mediated inhibition
of MAPK signaling
MAPK family members play an important role in the generation and fine-
tuning of inflammatory responses and are known to be activated by IFN-γ
receptor signaling [187, 196]. To address the role of specific members of the
MAPK family in the induction of pro-inflammatory chemokines in our model,
we used the JNK, p38 and ERK specific inhibitors: SP600125, SB203580 and
FR180204, respectively. Treatment with JNK and p38 inhibitors significantly
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reduced pro-inflammatory response induced by IFN-γ in lung endothelial cells.
Inhibition of p38 reduced CCL2 (MCP-1) levels by 28% whereas inhibition
of JNK blocked CXCL10 (IP-10), CCL2 (MCP-1) and CCL5 (RANTES) by
55%, 59% and 83% respectively (Figure 15a). Accordingly, JNK and p38 inhi-
bition blocked chemokine induction in the GC resistant condition upon com-
bining IFN-γ with PbNK65 extract. SB203580 inhibited CXCL10 (IP-10),
CCL2 (MCP-1) and CCL5 (RANTES) levels by 44%, 49% and 54%, whereas
SP600125 reduced CXCL10 (IP-10), CCL2 (MCP-1) and CCL5 (RANTES)
by 69%, 79% and 94%, respectively (Figure 15b). Inhibition of ERK failed
to reduce CXCL10 (IP-10) CCL2 (MCP-1) or CCL5 (RANTES) levels upon
challenge with IFN-γ and PbNK65 extract (Figure 16).
Since previous studies indicated that GCs inhibit MAPK family members
phosphorylation [94, 197], we investigated the effects of dexamethasone on p38
and JNK phosphorylation in endothelial cells stimulated with IFN-γ with and
without PbNK65 extract in the presence or absence of dexamethasone. We
found that dexamethasone blocked p38 and JNK phosphorylation upon chal-
lenge with IFN-γ (Figure 17a and 17b). Quantification of the Western blot
data revealed that, upon challenge with IFN-γ, dexamethasone reduced p38
and JNK phosphorylation on average by 69% and 61%. In unstimulated cells,
dexamethasone also blocked p38 and JNK phosphorylation by 58% and 63%,
respectively (Figure 17c and 17d). In contrast, when IFN-γ was combined with
PbNK65 extract dexamethasone failed to inhibit p38 and JNK phosphoryla-
tion by more than 14% and 4% (Figure 17a–17d). These data suggest that
dexamethasone inhibits IFN-γ-mediated induction of CXCL10 (IP-10), CCL2
(MCP-1) and CCL5 (RANTES) at least in part by blocking the activation of
p38 and JNK. Furthermore, this inhibitory mechanism is impaired in the GC
resistant condition.
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(a)
(b)
Figure 15: p38 (SB) and JNK (SP) inhibitors impair pro-inflammatory cytokine
expression in lung endothelial cells. L2 MVECs were stimulated with IFN-γ (20
ng/mL) (a) or IFN-γ (20 ng/mL) and PbNK65 extract (PbNK65, 107 infected
RBCs/mL) (b) in the presence of JNK inhibitor SP600125 (SP, 20 µM) or p38
inhibitor SB203580 (SB, 5 µM) for 24 hours. Protein levels of CXCL10 (IP-10),
CCL2 (MCP-1) and CCL5 (RANTES) were determined by ELISA. Statistical
significance was evaluated using ANOVA (* p <0.05, ** p <0.01, *** p <0.001).
Data represent combined results from 3 independent experiments.
4.4 Discussion
Since STAT1 signaling mediates transcription of a significant subset of IFN-γ-
induced genes, we investigated the effects of GCs on STAT1 activation. In our
model, GCs failed to affect STAT1 expression and phosphorylation. Conversely,
GCs suppress STAT1 phosphorylation via SOCS1 induction in macrophages ac-
tivated with TLR-ligands [198]. Another study showed that GCs inhibit STAT1
expression after long-term incubation in PBMCs stimulated with IFN-γ, but
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Figure 16: ERK inhibitor (FR) fails to impair pro-inflammatory cytokines
expression in lung endothelial cells stimulated with IFN-γ and PbNK65 ex-
tract. L2 MVECs were stimulated with IFN-γ (20 ng/mL) and PbNK65 extract
(PbNK65, 107 infected RBCs/mL) in the presence of ERK inhibitor (FR180204,
10 µM) for 24 hours. Protein levels of CXCL10 (IP-10), CCL2 (MCP-1) and
CCL5 (RANTES) were determined. Statistical significance was evaluated using
Mann-Whitney test. Data show combined results from 3 independent experi-
ments.
fail to affect its protein stability [199]. In macrophages challenged with type
I IFN, GCs antagonize transcriptional complex ISGF3, which is composed of
STAT1, STAT2 and IRF9, via depletion of GR-interacting protein 1 (GRIP1),
also known as transcriptional mediators/intermediary factor 2 (TIF2), used by
ISGF3 as co-activator [200]. GRIP1/TIF2 mediates anti-inflammatory actions
of GCs in macrophages via inhibition of cytokine gene transcription [201]. Fur-
thermore, conditional deletion of GRIP1 in obese mice results in macrophage
infiltration and inflammation in the liver [202].
Here, we also studied the effect of dexamethasone on the MAPK signal-
ing pathway – a known target of the anti-inflammatory action of GCs. We
found that JNK and p38 play an important role in the induction of pro-
inflammatory cytokines in lung endothelial cells upon stimulation with IFN-γ.
Dexamethasone inhibited JNK and p38 phosphorylation upon challenge with
IFN-γ. Together, these data suggest that inhibition of MAPK signaling is
a major mechanism of GC action in these cells. GCs have been shown to block
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(a) (b)
(c) (d)
Figure 17: Dexamethasone fails to suppress JNK and p38 activation after chal-
lenge with IFN-γ and PbNK65 extract. Western blot analysis of L2 MVEC
lysates stimulated for 24 hours with IFN-γ (20 ng/mL), IFN-γ and PbNK65
(107 infected RBCs/mL) extract in the presence or absence of dexamethasone
(Dex, 100 nM) was performed using anti-p-p38, anti-p38 (a), anti-pJNK and
anti-JNK (b) Ab. Data are representative of 3 independent experiments. (c,
d) Data from 3 independent experiments were normalized against actin and
percentage inhibition by dexamethasone was calculated based on the following
comparisons: Dex vs DMSO, IFN-γ+Dex vs IFN-γ, PbNK65+Dex vs PbNK65
and PbNK65+IFN-γ+Dex vs PbNK65+IFN-γ.
MAPK phosphorylation in various experimental models. For example, GCs
inhibit JNK via protein-protein interaction in HeLa cells. GR interacts with
JNK via a hormone-regulated JNK docking site in the GR ligand-binding do-
main and induces disassembly of JNK from mitogen-activated protein kinase
kinase 7 (MKK7) [197]. In macrophages challenged with LPS, dexamethasone
inhibits p38 but neither ERK nor JNK [94]. However, dexamethasone blocks
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JNK phosphorylation in HUVECs stimulated with TNF [203]. GCs also inhibit
JNK, p38 and ERK phosphorylation in human lung endothelial cells challenged
with TNF, IL-1β and H2O2 [204].
In this thesis, we show that the inhibitory actions of GCs on MAPK sig-
naling become impaired in lung endothelial cells upon challenge with PbNK65
extract and IFN-γ. Western blot analysis revealed that dexamethasone fails
to inhibit p38 and JNK phosphorylation, resulting in sustained inflammatory
chemokine expression and GC resistance.
Numerous studies confirm a highly complex interaction between GR and
MAPK signaling. In chapter 3, I showed that p-38 MAPK-mediated GR S211
phoshorylation remains unhampered upon challenge with IFN-γ and PbNK65.
GR phosphorylation by p38 mediates beneficial effects of GCs. For example,
GC-induced apoptosis in lymphoid cells requires S211 phosphorylation of GR
by p38 [172]. Similarly, p38 activation by LPS in a model of acute lung injury
enhances anti-inflammatory actions of GR [67]. In contrast, JNK negatively
regulates the activities of GR by S226 phosphorylation, resulting in enhanced
nuclear export and termination of GR signaling [175]. In chapter 3, I found
that stimulation with IFN-γ and PbNK65 fails to enhance GR S226 phospho-
rylation. MAPK and GR interaction might also result in GC resistance. In
airway smooth muscle cells, p38 phosphorylates GR at S203 acting as a negative
regulator of GR transcriptional activity [205]. Inhibition of JNK enhances GR
binding to GREs in mouse hippocampal cells [206]. Moreover, JNK activation
by cholesterol impairs GR-mediated transactivation [207].
MKP-1 (DUSP1) is an important mediator of GC inhibitory actions on
MAPK signaling [74, 208]. MKP-1 (DUSP1) inhibits p38 in macrophages stim-
ulated with TNF and also blocks JNK and p38 in macrophages challenged with
LPS [94, 209]. Furthermore, in macrophages from patients with severe asthma,
the activity of p38 MAPK was increased while expression of MKP-1 (DUSP1)
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was reduced [126]. MKP-1 (DUSP1) also blocks p38 in endothelial cells [203].
We observed increased mRNA levels of MKP-1 (DUSP1) after stimulation with
IFN-γ and PbNK65 compared to IFN-γ alone in the presence of dexamethasone.
Moreover, we evaluated the expression of GILZ upon challenge with IFN-γ and
PbNK65 and dexamethasone and we found no difference when compared with
IFN-γ alone. This indicates that GC-mediated transactivation is not affected
by the GC resistance induced by PbNK65. GILZ has been suggested to in-
duce MKP-1 (DUSP1) expression. However, silencing of GILZ (Tsc22d3) in
HUVECs failed to alter the pro-inflammatory response to TNF [210, 211].
In conclusion, we here show that PbNK65 extract in combination with IFN-
γ impairs GC-mediated transcriptional inhibition of inflammatory chemokines
in murine lung endothelial cells. In contrast, lung endothelial cells remain GC
sensitive when challenged with IFN-γ alone. GCs block activation of JNK and
p38 upon challenge with IFN-γ. However, PbNK65 extract interferes with the
inhibitory actions of GCs on p38 and JNK.
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5 Conclusion
MA-ARDS remains an often lethal and poorly understood complication of
malaria infections [2, 7]. Currently efficient treatment for this syndrome is
not available. In an in vivo model of MA-ARDS, extremely high doses of GCs
were needed to block MA-ARDS. Furthermore, GCs failed to inhibit the ex-
pression of pro-inflammatory cytokines and chemokines in the lungs of infected
mice, suggesting that malaria can decrease GC sensitivity [8]. In this thesis,
we investigated the molecular mechanisms of malaria-induced GC resistance.
Since endothelial cells play an important role in malaria, we studied GC sen-
sitivity of lung endothelial cells challenged with PbNK65 and IFN-γ. IFN-γ
expression is increased in the lungs of PbNK65-infected mice [8]. NK cells are
the earliest source of IFN-γ during both blood and liver stage of malaria. Upon
initiation of adaptive immune response T cells become the major producers of
IFN-γ [145]. We found that lung endothelial cells remain GC sensitive upon
challenge with IFN-γ. In contrast, upon stimulation with PbNK65 and IFN-γ
the cells become GC resistant. We found that GCs block p38 and JNK sig-
naling upon challenge with IFN-γ alone. However, when PbNK65 is combined
with IFN-γ, GCs fail to block MAPK signaling and GC resistance occurs (Fig-
ure 18). Interestingly, GC-mediated transactivation remains unaffected upon
challenge with PbNK65 and IFN-γ.
Only a limited number of studies addressed GCs as a potential therapy
against complications of malaria. During cerebral malaria, infected RBCs ad-
here to the endothelium in the brain leading to enhanced expression of adhesion
molecules and blood brain barrier damage [6]. GCs exert diverse actions on en-
dothelial cells that could be particularly beneficial in the treatment of cerebral
malaria. For example, GCs preserve endothelial barrier integrity via upregula-
tion of junctional proteins such as claudin-5 and VE-cadherin [113, 114, 115].
Moreover, GCs downregulate the expression of MMP-9, an enzyme involved in
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Figure 18: PbNK65 extract in combination with IFN-γ impairs inhibitory ef-
fects of GCs on MAPK in lung endothelium. (a) IFN-γ signals through IFNGR
and activates STAT1 and MAPK signaling. STAT1 homodimer translocates to
the nucleus and activates gene transcription. MAPKs induce gene expression
via specific transcription factors (TFs). Upon entering the cell, GC bind to
GR and inhibit activation of JNK and p38 induced by IFN-γ. This reduces
pro-inflammatory gene expression, including CXCL10 (IP-10), CCL2 (MCP-1)
and CCL5 (RANTES). (b) When cells are stimulated with IFN-γ and PbNK65
extract, GCs fail to block p38 and JNK activation. Therefore, transcription of
pro-inflammatory genes remains unaffected.
the cleavage of junctional proteins [116, 117, 118]. GC resistance may explain
the failure of two clinical trials performed in patients with cerebral malaria
[212, 213]. Therefore, it is important to investigate GC resistance in malaria
in more detail.
GCs could also be considered as a potential therapy for MA-ARDS. This
syndrome is characterized by severe inflammation and massive leukocyte infil-
tration due to endothelial barrier damage in the lungs [2]. Besides preserving
endothelial barrier integrity, several other actions of GCs on endothelium would
be beneficial in MA-ARDS. For example, GCs have been shown to downregulate
60
cytokine and chemokine expression in endothelial cells [98, 97, 103]. This could
reduce leukocyte infiltration. Moreover, GCs also inhibit pro-inflammatory
transcription factors such NF-κB and AP-1 [96]. The flipside of the coin is the
fact that the use of GCs in patients with ARDS remains controversial. Clinical
trials provide conflicting data on the timing and dosage of treatment. Short
term treatment with high doses of GCs fails to improve the outcome of pa-
tients with ARDS. Prolonged treatment with low doses of GCs seems a more
promising therapy, but additional studies are still required [214].
GC resistance has been described in various diseases, including leukemia,
asthma and COPD [130, 123]. Diverse mechanisms underlying the GC re-
sistance in those diseases have been proposed including activation of MAPK
pathway. In PBMCs from patients with asthma, lower ligand affinity of GR
was observed. This decrease was also mimicked by challenge with IL-2 and
IL-4, which impaired inhibition of pro-inflammatory mediators and induction
of IL-10 by GCs. Inhibition of p38 MAPK restored GC sensitivity suggesting
that GR phosphorylation by p38 decreases its ligand affinity and causes GC
resistance [215]. Another study showed that IL-2 and IL-4 activate p38 MAPK
and impair GR S211 phosphorylation and nuclear translocation in PBMCs from
healthy subjects [169]. In alveolar macrophages from patients with asthma, im-
paired induction of MKP-1 (DUSP1) by GCs results in sustained p38 MAPK
activation and pro-inflammatory cytokine and chemokine release [126]. In this
thesis, we show that MAPK-related GC resistance occurs in lung endothelial
cells upon challenge with Plasmodium berghei NK65 and IFN-γ.
The effects of GC and the regulation of GC sensitivity have been extensively
studied in various immune cells [86]. However, a limited number of studies
addressed these issues in endothelial cells, which represent an important target
for GCs. Several studies investigated the effects of GC on endothelial cells in
inflammatory diseases. For example, signaling through endothelial GR plays a
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beneficial role in models of sepsis. Mice with an endothelium-specific deletion
of GR show increased mortality, higher levels of TNF, IL-6 and nitric oxide in
comparison with control mice after challenge with LPS [216]. GR deletion in
HUVECs treated with LPS increases NF-κB levels and IL-6 levels suggesting
that endothelial GR plays a crucial role in the regulation of the NF-κB pathway
and nitric oxide synthesis. Moreover, mice lacking endothelial GR pre-treated
with dexamethasone show increased NF-κB activity compared to wild-type
mice after LPS injection [217]. Endothelial GR also plays an important role in
the atheroprotective actions of endogenous GCs. Apolipoprotein E (ApoE) KO
mice lacking endothelial GR subjected to a high-fat diet developed more severe
atherosclerotic lesions and showed increased macrophage recruitment [218].
In this thesis, we performed genome wide analysis of GC action on IFN-
γ-induced inflammation in lung endothelial cells. We show that GCs inhibit
several clusters of pro-inflammatory mediators and induce a number of protec-
tive molecules. To our knowledge, this is the first high-throughput analysis of
GC actions on IFN-γ-induced transcriptome in endothelial cells. Moreover, we
identify a novel mechanism by which GCs block pro-inflammatory chemokine
expression in lung endothelial cells challenged with IFN-γ. We also show that
malaria parasites interfere with anti-inflammatory actions of GCs in lung en-
dothelial cells and impair GC-induced MAPK inhibition.
This work offers an interesting explanation of our previous observation in
the preclinical model of MA-ARDS, namely that GCs could only block the pul-
monary inflammation at extremely high dosages and were even then not able
to downregulate the expression of several inflammatory genes in the lungs [8].
As future perspectives, we propose to validate our in vitro results in mice and
use MAPK inhibitors. MAPK inhibitors could help to reverse GC resistance
in patients with asthma [215]. The remaining question in our in vivo model of
MA-ARDS is whether MAPK inhibitors should be combined with anti-malarial
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treatment and/or with GCs. MAPK inhibitors combined with GCs might exert
too much immunosuppression. On the other hand, we show that MAPK inhibi-
tion blocks the expression of pro-inflammatory chemokines in lung endothelial
cells. Therefore, MAPK inhibitors combined with anti-malarial compounds
might be a more interesting idea to validate our data in vivo. We also aim to
validate the data obtained so far in the human in vitro model with P. falci-
parum. Moreover, in view of the complex pathogenesis of MA-ARDS, we think
that extending our in vitro model to other cell types such as macrophages or
T cells would provide further interesting insights into how GCs resolve lung
inflammation.
In conclusion, this doctoral thesis provides a unique view on the regula-
tion of IFN-γ-induced lung inflammation and identifies PbNK65 as a novel
inducer of GC resistance in lung endothelial cells. Throughout different chap-
ters in this work, we confirmed that GC resistance is not caused by failure
in GR translocation or phosphorylation. We also show that the STAT1 path-
way is not a main target of GCs in our model. In contrast, GCs decreased
IFN-γ-induced MAPK signaling and impaired inhibition of MAPK signaling
upon challenge with PbNK65 and IFN-γ results in a sustained inflammatory
response. Genome-wide analysis of GC actions on lung endothelial cells chal-
lenged with IFN-γ further confirmed GC sensitivity of these cells. Our research
provides novel insights into the actions of GCs during lung inflammation and
also confirms the importance of endothelial cells as a target for GCs. We hope
that this work will stimulate further research in different areas including MA-
ARDS, ARDS and vascular biology.
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Acronyms
11β-HSD2 11β-hydroxysteroid dehydrogenase 2. 7, 18
11β-HSD1 11β-hydroxysteroid dehydrogenase 1. 7, 18
AF activation function. 7, 8
ALL acute lymphoblastic leukemia. 16
Angptl angiopoietin-like protein. 28
AnxA1 annexin A1. 13, 15
AP-1 activator protein 1. 8, 10, 13, 15, 28, 48, 60
ApoE apolipoprotein E. 61
ARDS acute respiratory distress syndrome. 2, 60, 63
AT1 angiotensin II type 1 receptor. 4
AT2 angiotensin II type 2 receptor. 4
BAG1 BCL2-associated athanogene 1. 17, 19
CBG corticosteroid-binding globulin. 6, 15
CCL CC chemokine ligand. 4, 5, 14, 15, 22, 23, 26, 28, 29, 32, 48, 51, 53, 59
CDK cyclin dependent kinase. 40
COPD chronic obstructive pulmonary disease. 16, 61
COX2 cyclooxygenase 2. 4
CXCL CXC chemokine ligand. 5, 14, 15, 22, 23, 26, 28, 29, 32, 48, 51, 53, 59
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DBD DNA binding domain. 7, 8
DC domain cassette. 3
DCs dendritic cells. 12
DUSP1 dual-specificity phosphatase-1. 13, 16, 26, 29, 32, 48, 57, 61
EPCR endothelial protein C receptor. 3
ERK extracellular signal-regulated kinase. 47, 48, 49, 51, 53, 55
FoxP3 transcription factor forkhead box P3. 12
GBP guanylate binding protein. 26, 28
GC glucocorticoid. 6, 7, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 23, 26, 28,
29, 32, 33, 29, 32, 40, 42, 46, 47, 49, 51, 53, 55, 57, 58, 59, 60, 61, 62, 63
GILZ glucocorticoid-induced leucine zipper. 8, 11, 12, 13, 26, 28, 29, 32, 57
GM-CSF granulocyte-macrophage colony-stimulating factor. 33
GR glucocorticoid receptor. 7, 8, 10, 11, 15, 16, 17, 18, 19, 20, 28, 33, 40, 41,
42, 43, 46, 55, 57, 59, 61, 63
GRE glucocorticoid response element. 7, 8, 10, 28, 33, 57
GRIP1 GR-interacting protein 1. 53
GRO-α growth related oncogene-α. 5
HDAC2 histone deacetylase 2. 10, 16, 17, 33
HPA hypothalamic-pituitary-adrenal. 6
HUVEC human umbilical vein endothelial cell. 17, 19, 46, 55, 57, 61
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IFNGR IFN-γ receptor. 47, 49, 59
IRF interferon regulatory factor. 28, 53
I-TAC interferon-inducible T cell α chemoattractant. 5
ICAM-1 intercellular adhesion molecule 1. 4, 5, 14, 15, 22, 26, 32
IFN-γ interferon-γ. 4, 11, 13, 14, 20, 22, 23, 24, 26, 28, 29, 32, 33, 29, 32, 40,
41, 42, 43, 46, 47, 48, 49, 51, 53, 55, 53, 57, 58, 59, 61, 62, 63
IL interleukin. 4, 5, 11, 12, 13, 14, 15, 22, 28, 33, 46, 48, 55, 61
IP-10 interferon-γ-induced protein 10. 5, 22, 23, 26, 29, 32, 48, 51, 53, 59
JAK Janus activated kinase. 47, 48
JNK c-Jun N-terminal kinase. 12, 40, 47, 48, 49, 51, 53, 55, 53, 55, 57, 58, 59
LBD C-terminal ligand-binding domain. 7, 8
LPS lipopolysaccharide. 12, 13, 28, 33, 48, 55, 57, 61
MA-ARDS malaria-associated acute respiratory distress syndrome. 1, 2, 20,
29, 59, 60, 62, 63
MAPK mitogen-activated protein kinase. 4, 12, 13, 20, 28, 40, 47, 48, 49, 51,
53, 55, 57, 59, 61, 62, 63
MCP-1 monocyte chemoattractant protein 1. 4, 5, 14, 15, 22, 23, 26, 29, 32,
51, 53, 59
MHC major histocompatibility complex. 13
MIG monokine induced by IFN-γ. 5, 22, 26, 28, 48
MIP-3α macrophage inflammatory protein-3α. 5
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MKK7 mitogen-activated protein kinase kinase 7. 55
MKP-1 map kinase phosphatase-1. 13, 15, 16, 26, 29, 32, 48, 57, 61
MMP-9 matrix metallopeptidase 9. 14, 15, 59
MR mineralocorticoid receptor. 7, 15
MS multiple sclerosis. 12, 14
NF-κB nuclear factor κB. 10, 13, 15, 28, 60, 61
NLS nuclear localization signal. 7, 8
NTD N-terminal transactivation domain. 7, 8
PBMC peripheral blood mononuclear cell. 16, 33, 46, 53, 61
PECAM-1 platelet endothelial cell adhesion molecule 1. 4, 5
PfEMP1 P. falciparum erythrocyte membrane protein 1. 3
PK protein kinase. 12
RANTES regulated on activation, normal T cell expressed and secreted. 22,
23, 26, 28, 29, 32, 48, 51, 53, 59
RBC red blood cell. 1, 3, 4, 23, 24, 32, 42, 43, 49, 51, 53, 59
SphK1 sphingosine kinase 1. 8, 15
STAT signal transducer and activator of transcription. 10, 20, 28, 47, 48, 49,
51, 53, 59, 63
TCR T cell receptor. 12
TGF-β transforming growth factor β. 12, 28, 33, 46
68
TIF2 transcriptional mediators/intermediary factor 2. 53
TIMP tissue inhibitor of metalloproteinases. 14, 15
TLR toll-like receptor. 12, 28, 53
TNF tumor necrosis factor. 4, 5, 6, 12, 22, 32, 33, 46, 48, 55, 57, 61
TNFRSf tumor necrosis factor receptor superfamily member. 28
Tsc22d3 TGF-stimulated clone 22 domain protein-3. 8, 26, 28, 29, 57
TTP tristetraprolin. 13, 15
VCAM-1 vascular cell adhesion molecule 1. 4, 5, 14, 15, 26, 32
VEGF vascular endothelial growth factor. 5
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